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Despite intense scientific efforts, the neuropathology and pathophysiology of
schizophrenia are poorly understood. Proteomic studies, by testing large numbers of
proteins for associations with disease, may contribute to the understanding of the
molecular mechanisms of schizophrenia. They may also indicate the types and locations
of cells most likely to harbor pathological alterations. Investigations using proteomic
approaches have already provided much information on quantitative and qualitative
protein patterns in postmortem brain tissue, peripheral tissues and body fluids. Different
proteomic technologies such as 2-D PAGE, 2-D DIGE, SELDI-TOF, shotgun proteomics
with label-based (ICAT), and label-free (MSE) quantification have been applied to the
study of schizophrenia for the past 15 years. This review summarizes the results,
mostly from brain but also from other tissues and bodily fluids, of proteomics studies in
schizophrenia. Emphasis is given to proteomics platforms, varying sources of material,
proposed candidate biomarkers emerging from comparative proteomics studies, and
the specificity of the putative markers in terms of other mental illnesses. We also
compare proteins altered in schizophrenia with reports of protein or mRNA sequences
that are relatively enriched in specific cell types. While proteomic studies of schizophrenia
find abnormalities in the expression of many proteins that are not cell type-specific,
there appears to be a disproportionate representation of proteins whose synthesis and
localization are highly enriched in one or more brain cell type comparedwith other types of
brain cells. Two of the three proteins most commonly altered in schizophrenia are aldolase
C and glial fibrillary acidic protein, astrocytic proteins with entirely different functions,
but the studies are approximately evenly divided with regard to the direction of the
differences and the concordance or discordance between the two proteins. Alterations of
common myelin-associated proteins were also frequently observed, and in four studies
that identified alterations in at least two, all differences were downwards in schizophrenia,
consistent with earlier studies examining RNA or targeting myelin-associated proteins.
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THE NEED FOR PROTEOMICS STUDIES AND BIOMARKERS FOR
SCHIZOPHRENIA
Genomic studies of schizophrenia, using genome wide association studies (GWAS), copy
number variations (CNVs), microarrays, and next-generation sequencing (RNAseq) have linked
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schizophrenia with rare genetic variations (Sullivan et al.,
2012).There is strong evidence that there are no known
Mendelian variants identified for this disease. Instead, variations
of many genes with confirmed involvement of rare structural
variations and common variations with subtle effects are
considered to be involved in the etiology of the disease (Owen
et al., 2010). Genomics studies on schizophrenia have not
answered the main questions on the pathophysiology of the
disease, nor have they resulted in identification of diagnostic,
prognostic, or therapeutic biomarkers. In addition, current
research suggests that schizophrenia can arise from an interaction
between neurodevelopmental processes and environmental
effects (Albus, 2012).
Understanding schizophrenia as a complex disease therefore
requires determination of not only gene expression and DNA
variations, but also determination of the abundance and
modifications of various proteins, and their distribution at
gross anatomical, cellular, and subcellular levels. Proteomics
aims to unravel biological processes based on qualitative and
quantitative comparison of proteomes. It gives a different
level of understanding than genomics for several reasons.
First, the expression or function of proteins is modulated
at many diverse points, from transcription of DNA to post-
translational modifications (PTMs), and very little of this can
be predicted from analysis of nucleic acids alone. Second, there
is generally poor correlation between abundance of mRNA,
transcribed from DNA, and abundance of protein translated
from that mRNA. Third, many transcripts give rise to more than
one protein, through alternative splicing or alternative PTMs
such as phosphorylation, glycosylation, and acetylation, which
profoundly affect their activities and lead to multiple protein
products from the same gene.
Proteomic investigations have largely improved our
understanding of schizophrenia, based on quantitative and
qualitative identification of protein patterns in postmortem
brain tissue, peripheral tissues, and body fluids (Martins-de-
Souza et al., 2012b; Guest et al., 2013, 2014; Nascimento and
Martins-de-Souza, 2015). This has enhanced our knowledge of
complex protein networks and signal transduction pathways
affected in this disease, as discussed in detail below. In addition,
emerging proteomic platforms have facilitated the identification
of biomarker candidates by simultaneous measurement of
hundreds or thousands of molecules in non-hypothesis-driven
comparative proteomics studies. This approach established the
first blood-based test to aid in the diagnosis of schizophrenia
(Schwarz et al., 2010). The test encompassed 51 biomarkers with
an overall sensitivity and specificity of 83%. The clinical utility
of this test has been studied in terms of specificity compared
with other psychiatric disorders (Schwarz et al., 2012a), the ability
to identify the disease prior to clinical manifestation, (Schwarz
et al., 2012b) and the ability to define the complex schizophrenia
syndrome on the basis of molecular profiles (Schwarz et al.,
2014).
However, there is still an urgent need for biomarkers
that will help to improve the diagnosis and stratification of
patients and facilitate more effective treatments and care. The
field of proteomics is rapidly developing, with improvements
in mass spectrometry, peptide identification algorithms, and
bioinformatics. Larger studies, standardized sample collection
and processing, and highly sophisticated proteomics platforms
promise new diagnostic, prognostic, and therapeutic biomarkers
for schizophrenia.
PROTEOMICS STUDIES OF
SCHIZOPHRENIA
The history of proteomic studies of schizophrenia largely
recapitulates that of proteomics in general, driven over the past
few decades by advances in the instrumentation and analysis
of data for mass spectroscopy. We refer the reader to a recent
publication (Doerr et al., 2015), in which these developments are
reviewed for a general scientific audience.
The earliest proteomic investigations of schizophrenia
employed two-dimensional polyacrylamide gel electrophoresis
(2-D PAGE), combined with mass spectrometry (MS)
identification, mainly based on matrix-assisted laser
desorption/ionization-(MALDI)-time-of-flight (TOF)-TOF
instruments. Moreover, 2-D PAGE/MS and later on, 2-D
difference in-gel electrophoresis (DIGE)/MS are the most
reported platforms in the study of postmortem brain tissues.
As summarized in Table 1, 14 out of 25 proteomic studies on
autopsy brain tissue from people with schizophrenia used 2-
D PAGE/MS or 2-D DIGE/MS alone, and 2 studies employed
combinations of these platforms with shotgun proteomics.
Since its introduction in 1975 (O’Farrell, 1975), 2-D PAGE,
combined with MS, has been widely used in proteomics
studies. The platform is based on several steps of protein
separation, detection, quantification and identification. Proteins
are separated in two steps: by isoelectric point (pl) through
isoelectric focusing on immobilized pH gradient (IPG) strips,
followed by separation by molecular weight (MW) using SDS–
PAGE. Proteins are detected using different staining protocols,
and differences in abundances are quantified by image analysis
software. The protein identification is based on excision of the
2D-spots of interest, enzymatic digestion (usually with trypsin),
and analysis of the masses of these peptides by mass spectrometry
[MALDI-TOF-MS or liquid chromatography (LC)–MS/MS].
Each protein produces a specific combination of peptide masses,
known as a peptide mass fingerprint, which allows identification
by comparison with database of fingerprints derived from protein
sequences. To minimize ambiguity from gel-to-gel differences in
2-D PAGE, DIGE was introduced in 1997 (Unlü et al., 1997).
DIGE combines multiple samples and internal standards in
one gel by the fluorescent labeling of different samples with
different cyanine dyes. This eliminates the need for technical
replicates heavily used in conventional 2-D PAGE and improves
reproducibility and sensitivity.
The advantages and limitations of this platform are well-
established (Rabilloud and Lelong, 2011). The key advantages
are high reproducibility, robustness, separation of intact proteins,
visualization, and detection of PTMs, and cost-effectiveness of
the procedure. A major disadvantage of any gel-based system,
as recognized throughout the years, is limitation in the analysis
Frontiers in Cellular Neuroscience | www.frontiersin.org 2 February 2016 | Volume 10 | Article 18
Davalieva et al. Proteomics Research in Schizophrenia
TABLE 1 | Proteins with altered abundance in schizophrenia obtained by comparative proteomics studies of several human brain regions.
Number of
proteins
with altered
abundances
Brain region
(BA)**
Some of the proteins with
altered abundances in
schizophrenia compared to
controls*
Processes and pathways
affected
Study design Method References
FRONTAL CORTEX
8 proteins 10 DPYSL2↓ ALDOC↑ GFAP↓ Differentiation,
neurogenesis, glycolysis,
development and
organization of the central
nervous system
Individuals with
schizophrenia (n = 24),
bipolar disorder (n = 23),
major depressive
disorder without
psychotic features (n =
19) and unaffected
controls (n = 23)
2-D PAGE/MS Johnston-Wilson
et al., 2000
PREFRONTAL CORTEX
50 proteins 9 white and
gray matter
PKM1↓; PKM 2↓; ACO2↓;
HK1↓; PRDX1↓; PRDX2↓;
ALDOC↓; ALDOA↓;
HSPA1↓;HSPA2↓; HSPA5↓;
HSPA8↓; TUBA2↓; TUBA6↓;
TUBB5↓; ENO1/2↓; GSN↓;
GLUL↓; ACTA/B/C↓;
MDH1↓; SPTAN1↓; CNP↓;
DNM1/2↓; DPYSL2↓;
DPYSL5↓; DPYSL4↓;
SEPT3↓; TF↑; GSTM3↓,
GSTTLp28↓;
Mitochondrial function,
oxidative stress responses,
peroxisomal function,
cytoskeletal dysfunction,
protein trafficking
10 schizophrenia and 10
well-matched control
individuals
2-D DIGE/MS Prabakaran et al.,
2004
15 proteins 9
(dorsolateral)
DPYSL3↑; PHGDH↑;
SEPT5↑; TCP1↑; PGLS↑;
DNM1↑; ERP29↑; ALB↑;
ENO2↓; GFAP↑; GDA↓;
NEFL↓; PACSIN1↓; TF↓;
ATP6V1B2↓
Development of the central
nervous system, energy
metabolism, cytoskeletal
dysfunction
35 individuals with
schizophrenia, 35 with
bipolar disorder and 35
controls
2-D PAGE/MS Pennington et al.,
2008
16 proteins 9
(dorsolateral)
gray matter
LAMP↑; STXBP1↑; BASP1↑;
NCAM↑; PHB↓; CNTN1↓;
CKB↑; HBB↓; GNAI1↑;
TUBB/A↑; ATP6V1B2↑;
VDAC1↓
Synaptic function,
metabolism, signaling,
cytoskeletal dysfunction
Pooled samples from
schizophrenia, bipolar
disorder and control
cases (n = 10 per group)
2-D DIGE/MS
1-D/LC-MS/MS
Behan et al., 2009
Targeted one
protein
expression
9
(dorsolateral)
APOA1↓ May have role in neuronal
and glial metabolism
16 schizophrenia and 16
well-matched controls
Western blot Huang et al., 2008
24 proteins 46 (left
dorsolateral)
MBP↓; TF↓; ALDOC↑;
PGK1↑; ACO2↑; MDH1↓;
ATP5H↑; ATP5A1↑;
UQCRC1↓; HSP90AA1 ↓;
HSPD1↑; INA↑; PCMT1↑;
GFAP↑; NEFL↓; DNM1↑;
CFL1↓; CRYM↓; GNB1↑;
DPYSL2↑;ACTG1↓
Alterations in
oligodendrocytes, energy
metabolism, glycolysis,
oxidative stress, cytoskeletal
dysfunction, cell signaling
pool of 9 schizophrenia
patients and pool of 7
paired controls
2-D PAGE/MS Martins-de-Souza
et al., 2009a
84 proteins 46
(dorsolateral)
SIRPA↓; SIRPB1↓; PRDX2↑;
PRDX6↑; PLEC↑; VIM↑;
LMNB2↑; DES↑; TUBB2B↑;
TBCB↑; KIF21A↑; MAP1A↑;
MAP2↑; MAP6↑; EPB41L1↑;
SH3GL2↑; PEBP1↑; BSN↑;
HOMER1↑; STRN↑; MOG↓;
CSNK2A1↑; MYO1D↓; HK1↑;
PFKM↑; GAPDH↑; CNP↓
Immune system,
cytoskeleton assembly,
calcium homeostasis,
energy metabolism,
glycolysis
9 schizophrenia patients
and 7 controls
ICPL
/IEF/LC-MALDI
Martins-de-Souza
et al., 2009c
(Continued)
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TABLE 1 | Continued
Number of
proteins
with altered
abundances
Brain region
(BA)**
Some of the proteins with
altered abundances in
schizophrenia compared to
controls*
Processes and pathways
affected
Study design Method References
32 proteins 46
(dorsolateral-
white
matter)
NEFL↓; NEFM↑; NEFH↓;
VIM↑; TUBB↓; YWHAE↑;
YWHAZ↓; DPYSL2↑;
DPYSL3↑; DPYSL5↑;
PCMT1↑; STMN1↓; GDI1↑;
ENO1↓; ALDOC↓; IMPA1↑;
TPI1↓; PRDX4↓;
PDE8B↓,PLP1↑
Cytoskeletal dysfunction,
signal transduction, energy
metabolism
35 schizophrenia, 35
bipolar disorder and 35
controls
2-D DIGE/MS English et al., 2009
41 protein
spots
NS (left
dorsolateral
synapse
enriched
fractions)
PKM↓; ATP6V1B2↑;
ATP5B↑; GDF2↓; GNAQ↑;
PEBP1↑; ANXA10↑; CKB↑;
GNB3↑; PPA2↑; ALDOC↑;
AK4↑; ANXA2↓; HDGF↑;
MLF2↑; ATP5H↑; VDAC1↑;
PDYN↑;
Energy metabolism,
neurotransmission/signaling
8 schizophrenia patients
and 7 controls
2-D PAGE/MS Smalla et al., 2008
Targeted one
protein
expression
46
(dorsolateral)
HINT1↓ May have role in cellular
stress and apoptosis
9 schizophrenia patients
and 7 controls
Western blot Varadarajulu et al.,
2012
Biomarker
panel of 10
peaks
NS
(dorsolateral)
No protein identifications
(sensitivity and specificity of the
panel 70%)
34 schizophrenia patients
and 35 matched controls
SELDI-TOF-MS Mei et al., 2006
Biomarker
panel of 21
protein peaks
NS
(dorsolateral)
CD58 ↓; CALM1↓; MAGOH↓;
MAXb↓; RGS11↓; UCHL1↓;
CEBPZ↓; HSPD1↓; PGAM1↓;
ENO2↓; GLUL↓; PPA2↓;
YWHAE↓; ALDOC↓; PNP↓;
NKX2-4↓; DECR2↓; MTAP↓;
BYSL↓; SMPD1↓; ANKRD12↓;
Cell metabolism, glycolysis,
intracellular signaling,
oxidative stress
17 schizophrenia
patients, 20 bipolar
disorder patients and 20
normal controls
SELDI-TOF-MS Novikova et al.,
2006
ANTERIOR CINGULATE CORTEX
36 proteins 24 (gray
matter)
DPYSL2↑; CRMP1↑;
ALDOC↓; DNM1↑; GFAP↓;
PPP1CA↓; CS↓; CA1↑; TF↓;
IDH3B↓; ACAT2↑; SOD1↑;
DDAH1↓; ANXA1↑; ANXA5↑;
CKB↑; EHD3↑; STMN1↑;
PHB↑;
Energy metabolism,
oxidative stress, cytoskeletal
dysfunction, protein
trafficking, development and
organization of the central
nervous system
10 schizophrenia patients
and 10 healthy controls
2-D PAGE/MS Clark et al., 2006
27 proteins 24 (white
matter)
DPYSL2↓; ALDOC↓; CS↑;
CBR1↓; ATP5A1↑; IMPA1↑;
GPD1↓; LDHA↓; NEFL↓;
ATP6V1A↑; PSMB4↑;
PGAM1↓
Energy metabolism,
oxidative stress response,
cytoskeletal dysfunction,
cellular signaling
10 schizophrenia patients
and 10 healthy controls
2-D PAGE/MS Clark et al., 2007
19 proteins NS ACO2↑; ALDOA↑; CRMP1↑;
DPYSL2↑; SRI↓; CKB↓;
Energy metabolism,
glycolysis, cytoskeletal
dysfunction
15 schizophrenia
patients, 15 bipolar, 15
major depressive
disorder and 15 healthy
controls
2-D PAGE/MS Beasley et al., 2006
32 proteins NS DPYSL2↑; CRYAB↑;
PRDX6↓; ALDOC↑; GLUL↑
Energy metabolism, cell
communication/ signal
transduction, cytoskeletal
dysfunction
11 schizophrenia patients
and 8 healthy controls
2-D PAGE/MS Martins-de-Souza
et al., 2010b
(Continued)
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TABLE 1 | Continued
Number of
proteins
with altered
abundances
Brain region
(BA)**
Some of the proteins with
altered abundances in
schizophrenia compared to
controls*
Processes and pathways
affected
Study design Method References
143 proteins 24
(enrichment
of the
postsynaptic
density)
ARF6↑; ARFGAP1↑; AP2B1↑;
RAB11FIP5↑; AP2M1↓;
ADRBK1↓; DNM1↑; HSPA6↓;
HSPA8↓; RAP1A↑; GRIA2↓;
MAPK3↓; SHANK3↓;
SYNPO↓; MYL6↓; CYFIP2↓;
ATP6V0A1↓; PRDX1↓;
ESYT↑; GNAS↓; CAMK2B,
CAMK2D↓; CAMK2G↓;
CALM2↓; VDAC1↓; VDAC2↓
Endocytosis, long-term
potentiation, calcium
signaling pathway
10 schizophrenia patients
and 10 healthy controls
Label-free
LC−MS/MS
Föcking et al., 2015
CORPUS CALLOSUM
34 proteins NS NEFL↓; NEFM↓; GFAP↑;
ACTG1 ↓; ACTB ↓; TUBB↓;
INA↑; ACTR1A↑; COTL1↑;
ATP5B↓; ARHGDIA↑;
STMN1↑; DPYSL2↓;
YWHAH↓; HSPA8↓;
HSPA1L↓; HSPA5↑; GSTP1↑;
SOD1↑; CKB↓; PRDX2↓;
UCHL1↑; PARK7↑; FTH1↓;
LDHB↓; ENO2↓;
Cytoskeletal dysfunction,
oxidative stress, glycolysis,
neuroprotective dysfunction
10 schizophrenia patients
and 10 healthy controls
2-D PAGE/MS Sivagnanasundaram
et al., 2007
65 proteins NS INA↓; CLTC↓; VCAN↓;
FSCN1↑; GSN↓; NEFL↓;
HAPLN2↓; NEFM↓; NEFH↑;
TUBA1A↓; TUBA4A↓;
TUBB2B↓; TUBB4B↑;
TUBB3↑; TUBB6↑;STMN1↑;
VIM↑; CNP↓; ENO1/2↑;
ATP5A1↓; ALDOA↓;
GLUD1↑; GAPDH↓; PYGB↓;
PYGM↓; CRYL1↓; MDH1↓;
PRDX1↓; PKM↑; SOD1↓;
TPI1↓; HINT1↑; MOG↓;
YWHAB/H/Z/G↓; CRYAB↓;
HSPA6↑; UBE2N↑; MBP↓;
ATP6V1B2↑;
Cell growth and
maintenance, energy
metabolism, cell
communication and
signaling, protein
metabolism, transport and
myelination
9 schizophrenia patients
and 7 healthy controls
Label-free nano
LC-MS/MS
Saia-Cereda et al.,
2015
Targeted one
protein
expression
NS S100B↓ Disturbed oligodendrocyte
maturation
9 schizophrenia patients
and 7 healthy controls
2-D nano
LC/MS Western
blot
Steiner et al., 2014
TEMPORAL LOBE
25 proteins 22 (left
posterior
superior-
Wernicke’s
area)
CKB↑; ALDOC↓; TPI1↑;
GAPDH↓; PGAM1↑; ENO2↑;
ATP6V1A↑; ATP5A1↓;
QDPR↑; PRDX6↑; GFAP↑;
PEBP1↑; ACO2↑; TUBB↓
Energy metabolism,
glycolysis
9 schizophrenia patients
and 6 healthy controls
2-D PAGE/MS Martins-de-Souza
et al., 2009b
37 proteins 38 (left
anterior)
MOG↓; MBP↓; GFAP↓;
UBE2N↓; CNP↓; PPP3CA↓;
SPTAN1↓, YWHAH↓;
YWHAZ↓; YWHAG↓;
ALDOC↓; HIST1H3A↓; CA2↓;
RPS10↓; SLC9A3R1↑;
TUBB↑; NEFL↓; NEFM↓
Oligodendrocyte-myelin
regulated proteins,
regulation Ca2+
homeostasis, energy
metabolism
5 schizophrenia patients
and 4 healthy controls
ICPL
/IEF/LC-MALDI
Martins-de-Souza
et al., 2009d
(Continued)
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TABLE 1 | Continued
Number of
proteins
with altered
abundances
Brain region
(BA)**
Some of the proteins with
altered abundances in
schizophrenia compared to
controls*
Processes and pathways
affected
Study design Method References
HIPPOCAMPUS
34 proteins anterior and
posterior
Anterior (CKB↓; ATP5H↑;
LDHB↓; NME1↑; COX5A↑;
COX6B1↓; PRDX2↓;
PRDX6↓; SOD1↓; UBE2N↑;
PHB↑; HSPA1B↓; HSPA9↓;
ACTB↓; VIM↑; NEFM↓;
STMN1↑; FABP7↓; YWHAZ↑;
YWHAG↑; YWHAE↑;
ANXA5↑; ATP6V1A↓)
Posterior (PGAM1↑; CKB↑;
TALDO1↑; GSN↑; ACTB↑;
TUBA1↓; TUBB4↓; STMN1↑)
Energy metabolism,
oxidative stress, altered
neurotransmission,
mitochondrial dysfunction,
abnormal neuronal and glial
cytoarchitecture
Anterior hippocampus (7
schizophrenia patients
and 7 controls)
Posterior hippocampus
(9 schizophrenia patients
and 9 controls)
2-D PAGE/MS Nesvaderani et al.,
2009
108 proteins mid GFAP↓; HSPA8↓; CTSD↑;
STMN1↑; SOD1↑; DPYSL3↓;
NEFL↓; FSCN1↓; ANXA6↓;
TUB↑; SEPT11↓; SNCA↓;
ATP6V1B2↓; ENO1↓;
YWHAE↓; PCMT1↓;
SPTAN1↓; PRDX1↓;
cytoskeletal and metabolic
changes, clathrin-mediated
endocytosis
20 subjects with
schizophrenia, 20
subjects with bipolar
disorder, and 20 control
cases
2-D DIGE/MS Föcking et al., 2011
MEDIODORSAL THALAMUS
10 proteins
(2-D) 41
proteins
(shotgun)
NS TKT↑; GSTP1↑; PGAM1↑;
GAPDH↑; QDPR↑; TPI1↑;
YWHAZ↓; CFL1↑; MBP↑;
MOG↑; NEFM↓; PRKCG↑;
GFAP↓; HSPA8↓; VIM↑;
HSPA1A↑; ACT↑; GLUL↑;
MAP1A↑; MAPT↓; SYT5↑;
SYN3↑; SEPT2↓
Energy metabolism,
oligodendrocyte
metabolism, cytoskeleton
assembly
Samples from 11
schizophrenia patients
and 8 controls
2-D PAGE/MS
ICPL/IEF/LC-
MALDI
Martins-de-Souza
et al., 2010a
Targeted one
protein
expression
NS HINT1↑ May have role in cellular
stress and apoptosis
11 schizophrenia patients
and 8 controls
Western blot Varadarajulu et al.,
2012
*Proteins found in more than one independent study are highlighted in bold. The arrows indicate the increase (↑) or decrease (↓) of the protein level in the schizophrenia group compared
to control group(s). **Brodmann area. NS, Brodmann area not specified or not applicable.
of hydrophobic (membrane) proteins, high molecular weight
proteins (Mw > 100 kDa), and highly acidic (pI < 3), or basic
(pI > 9) proteins. Another important drawback is the limitation
of the dynamic range of detection, as highly abundant proteins
typically mask the identification of less abundant proteins
with similar pI and MW. However, efforts to overcome these
limitations are improving resolution (Butt and Coorssen, 2005)
and increasing dynamic range (Wright et al., 2014a,b).
“Shotgun” proteomic techniques do not employ gels and
are aimed to touch all possible targets at once. These are
powerful tools for studying large-scale protein expression and
characterization of complex biological systems. Shotgunmethods
begin with digestion of the whole proteome of interest, followed
by high resolution separation of the resultant peptides by liquid
chromatography (LC) and their identification based on tandem
mass spectrometry (MS/MS) data; (Link et al., 1999). Increased
resolution can be achieved by including pre-fractionation steps
prior to LC-MS/MS. Pre-fractionationmethods can include other
types of chromatography (e.g., affinity chromatography), initial
separation by isoelectric focusing (IEF), or one dimensional
sodium dodecyl sulfate PAGE (1-D SDS PAGE). In the case of IEF
and 1-D SDS PAGE, gels are divided into a number of pieces, and
each piece is subjected to digestion and subsequent LC-MS/MS.
IEF pre-fractionation has been used in 3 published studies of
schizophrenia, and 1-D SDS PAGE pre-fractionation in one
(Behan et al., 2009; Martins-de-Souza et al., 2009c,d, 2010b). In
addition, the number of protein identifications can be increased
by using two-dimensional liquid chromatography (2-D nano-
LC), which has been done on postmortem brain tissue (Steiner
et al., 2014). In shotgun proteomics, protein identification
relies strongly on computational resources that combine and
interpret data generated by MS/MS (Haas et al., 2006). The
quantification of proteins in a shotgun-MS comparative analysis
can be based on labeled or unlabeled peptides. Labeling
methods used in schizophrenia proteomics studies include stable
isotope labeling methods, such as isobaric tags for relative
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and absolute concentration (iTRAQ) and isotope-coded protein
labeling (ICPL). However, most labeling-based quantification
approaches have potential limitations, such as increased time and
complexity of sample preparation, requirement for higher sample
concentration, high cost of the reagents, incomplete labeling,
requirement for specific quantification software, and a limited
number of samples (2–8) per analysis. Most of these limitations,
especially limits on number of samples, are eliminated in label-
free approaches (Patel et al., 2009). The quantification in label-
free proteomics is based on the theoretical assumption that
the chromatographic peak areas of peptides correlate with their
concentrations. Label-free proteomics analysis can be data-
dependent (DDA; Stahl et al., 1996) or data-independent (MSE;
Li et al., 2009), based on the selection of the peptide peaks for
identification. In schizophrenia studies, MSE has been used in
several studies of peripheral tissues and body fluids (reviewed
below) and is preferred over DDA because of the higher
percentage of protein identifications and higher coverage of the
proteome (Geromanos et al., 2009). MSE was used to identify
a serum biomarker panel capable of distinguishing first-onset
drug-naive schizophrenia subjects from healthy subjects. This
final panel was validated by immunoassay and later adapted into
the multiplex immunoassay platform (MAP) leading to the first
blood-based laboratory test for schizophrenia (Schwarz et al.,
2010).
The strengths of the shotgun approach are experimental
simplicity, greater proteomic coverage than gel-based platforms,
and accurate quantification. Its weaknesses involve technical
reproducibility, limited dynamic range, and informatics challenges
related to the enormous complexity of the generated peptide
samples (Domon and Aebersold, 2006). In addition, this
approach cannot identify proteins with multiple modifications
because the connection between the peptides that are analyzed
in the mass spectrometer and the protein(s) from which the
peptides originate is lost during proteolysis.
Surface-enhanced laser desorption/ionization time-of-flight
mass spectrometry (SELDI-TOF-MS) has also been applied in
the study of schizophrenia. SELDI-TOF is a variant MALDI-TOF
that makes use of chemically-modified surfaces to reduce the
complexity of biological samples prior to separation in the mass
analyzer. Its invention increased interest in using patterns from
mass spectra to differentiate samples with and without disease
(Wright, 2002). SELDI provided several important advantages,
such as ability to analyze complex biological samples with
minimal pre-processing, ease of handling, and high throughput.
However, over time, its lack of definitive protein identification
and low reproducibility, influenced mainly by sample processing
(Baggerly et al., 2004), became evident, and it is now used only
rarely. There are several SELDI-TOF-MS schizophrenia studies
of brain tissue and body fluids that appeared a decade ago, with
and without identification of the affected proteins (Huang et al.,
2006, 2008; Mei et al., 2006; Novikova et al., 2006; Craddock et al.,
2008).
While all the proteomics platforms discussed have their
strengths and weaknesses, it is becoming more widely accepted
that combinations of different proteomics methods can take
advantage of each method to increase the number of identified
and quantified proteins, to detect and characterize PTMs and to
increase statistical significance of the results. So far, schizophrenia
studies combining 2-D PAGE or 2-D DIGE with shotgun
proteomics are limited to one study of brain tissue (Behan et al.,
2009), one study of both brain tissue and cerebrospinal fluid
(Martins-de-Souza et al., 2010a) and one study of post-mortem
pituitary glands (Krishnamurthy et al., 2013). However, as the
growing number of studies demonstrate the power of combining
these two platforms, it seems that a combination of gel-based and
shotgun proteomics will be the best route to an understanding of
the biological pathways of schizophrenia and to the discovery of
reliable biomarkers for diagnosis, stratification and therapy.
Combinations of proteomics techniques other than gel-based
and shotgun proteomics reportedly result in high confidence
biomarker discovery. MALDI mass spectrometric imaging
(MSI), combined with high resolution top-down tandem MS
identification, has been used for the discovery of biomarkers for
neurodevelopment disorders (Ye et al., 2014) but has not yet
been used to study schizophrenia. MALDIMSI is a relatively new
imagining technique that is label-free and enables simultaneous
mapping of proteins and numerous molecules in tissue samples
with great sensitivity and chemical specificity (Seeley and
Caprioli, 2008). It has enabled discovery of tissue biomarkers
for various cancers. The top-down tandem MS approach differs
from the shotgun approach by directly analyzing intact proteins
and allowing assessment of protein modifications, such as PTMs
and sequence variants, with no prior knowledge (Kelleher, 2004;
Michalski et al., 2012). This combination is reported to be fast
and robust, and it has provided highly reproducible proteome
“snapshots” of anatomical regions in sections of infant rat brain.
It has high potential for future studies in schizophrenia.
CANDIDATE PROTEINS IMPLICATED IN
SCHIZOPHRENIA
Tissue Biomarkers
As schizophrenia is presumably a brain disease, the comparative
proteomic analysis of human postmortem brain tissue is of
highest interest as it may reveal the disease-related proteins.
This may help in the understanding the molecular mechanisms
of the disease and in addition indicate potential biomarkers as
candidates for diagnosis, prognosis, and therapy.
We have found 25 published articles on the proteomics of
human brain tissue in schizophrenia. These studies investigated
the relationship between schizophrenia and the protein profiles
of six distinct brain regions: frontal or prefrontal cortex, anterior
cingulate cortex, corpus callosum, temporal lobe neocortex,
hippocampus, and mediodorsal thalamus. Detailed review of
these studies regarding the study design, brain regions, number
of identified proteins with altered abundancies, some of the
candidate biomarker proteins, affected pathways in relation
to schizophrenia and proteomics platforms used, are given in
Table 1.
The most extensively studied brain region by proteomics
studies is prefrontal cortex (PFC). The primary functions of
PFC include the organization of thoughts and actions (cognitive
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control) such as willed action, decision making, and working
memory (Frith and Dolan, 1996; Miller and Cohen, 2001).
Individuals with schizophrenia exhibit poor working memory
(Park and Holzman, 1992), abnormal eye movements (Park
and Holzman, 1993), and abnormal executive functioning
(Velligan and Bow-Thomas, 1999). Well-known abnormalities of
dorsolateral (DL) PFC reported in schizophrenia include failure
to activate during the Wisconsin card-sorting test (Daniel et al.,
1991), decreased expression of calcium-binding proteins and
glutamic acid decarboxylase in interneurons (Hashimoto et al.,
2003), decreased density of spines on pyramidal cell dendrites
(Glantz and Lewis, 2000), and decreased cortical volume without
loss of neurons (Selemon et al., 1995).
The first proteomics study of schizophrenia (Johnston-
Wilson et al., 2000) used 2-D PAGE/MS to compare PFC,
specifically Brodmann area (BA) 10, of post mortem human
brains from individuals with schizophrenia, individuals with
other psychiatric disorders, and “controls” (i.e., individuals
who died without history of psychiatric disorder). Half of the
published proteomics studies on schizophrenia so far have
investigated the PFC, mostly dorsolateral PFC (Brodmann areas
9 and 46; Prabakaran et al., 2004; Mei et al., 2006; Novikova et al.,
2006; Huang et al., 2008; Pennington et al., 2008; Smalla et al.,
2008; Behan et al., 2009; English et al., 2009; Martins-de-Souza
et al., 2009a,c; Varadarajulu et al., 2012). Different proteomics
platforms were used, mostly gel-based platforms (2-D PAGE/2-
D DIGE) followed by shotgun proteomics or SELDI-TOF-MS.
Western blot was used for targeted analysis of particular proteins
of interest or validation of selected candidates.
The anterior cingulate cortex (ACC) is involved in emotion
and behavior (Luu and Posner, 2003). The association between
ACC and schizophrenia was based on abnormal activation of
the ACC during hallucinations (Cleghorn et al., 1990) and
task performances (Carter et al., 1997; Quintana et al., 2004)
and on histological abnormalities (Benes et al., 2001; Bouras
et al., 2001; Chana et al., 2003; Salgado-Pineda et al., 2003).
The differential protein expression between schizophrenia and
non-psychiatric groups was investigated in 4 studies using 2-D
PAGE/MS (Beasley et al., 2006; Clark et al., 2006, 2007; Martins-
de-Souza et al., 2010b) and one recent study using LC-MS/MS to
study expression of proteins in postsynaptic densities (Föcking
et al., 2015).
Neuropathological and neuroimaging studies have repeatedly
reported structural abnormalities of the corpus callosum (CC) in
schizophrenia, such as smaller volume, poor structural integrity
of the axonal fiber tracts, and decrease in density of axons
(Shenton et al., 2001; Mehler and Warnke, 2002; Innocenti
et al., 2003). CC has been investigated by two comparative
proteomics studies using 2-D PAGE/MS (Sivagnanasundaram
et al., 2007), and LC-MS (Saia-Cereda et al., 2015), respectively.
There is one more proteomics study of corpus callosum (Steiner
et al., 2014), which used targeted 2-D nano LC/MS and
western blot, to analyze S100B protein. In temporal lobe (TL)
neocortex, Wernicke’s area (posterior region of Brodmann area
22) and left temporal pole (Brodmann area 38) have been
implicated in the pathophysiology of schizophrenia because
of their roles in speech, language, and communication. There
are two comparative proteome analyses of these brain regions,
performed by 2-D PAGE/MS and shotgun proteomics (Martins-
de-Souza et al., 2009b,d).
Hippocampus and mediodorsal thalamus (MDT) are both
areas of interest in schizophrenia where early studies reported
structural abnormalities that were later called into question
(Dwork, 1997; Romanski et al., 1997; Harrison and Eastwood,
2001) andwere subsequently subjected to proteomics investigation.
There are 2 comparative studies of hippocampus using gel-
based proteomics (Nesvaderani et al., 2009; Föcking et al.,
2011), 1 comparative study of MDT using combination of 2-
D PAGE/MS and shotgun proteomics (Martins-de-Souza et al.,
2010a), and one targeted analysis of specific protein expression
in mediodorsal thalamus by Western blot (Varadarajulu et al.,
2012).
What is common to all of the proteomics studies of brain
tissue is that, regardless of the platform and brain region
analyzed, there has been constantly observed alteration of energy
metabolism expressed as disturbed levels of proteins included in
glycolysis, Krebs cycle, mitochondrial function, oxidative stress,
and various other energy pathways. Abnormalities of proteins
mediating synaptic function and signal transduction were also
observed.
The central pathway for energy metabolism is glycolysis.
Proteome analyses of different brain regions from individuals
with schizophrenia have consistently revealed a number of
differentially expressed glycolytic enzymes, as shown in Table 1.
Aldolase C and A (ALDOC/A), have been found with differential
abundance in 13 proteomics studies investigating FC, PFC,
ACC, CC, and TL. Alpha and gamma enolase (ENO1/2)
were found with differential abundance in 8 studies of
PFC, CC, TL, and hippocampus. Glyceraldehyde-3-phosphate
dehydrogenase (GAPDH), triosephosphate isomerase (TPI1),
and phosphoglycerate mutase 1 (PGAM1) were also found
with differential abundance in all of the investigated brain
regions except FC, while dysregulation of hexokinase (HK1)
was observed in two studies of PFC. Dysregulation of lactate
dehydrogenase complex (LDHA/B), which reduces pyruvate into
lactate and represents the intersection of key pathways of energy
metabolism, was observed in 3 studies analyzing ACC, CC, and
hippocampus.
Dysregulation of the Krebs cycle has also been implicated
in schizophrenia as a result of differential abundance of
several involved enzymes: such as aconitase 2 (ACO2), malate
dehydrogenase 1 (MDH1), and citrate synthase (CS). The
dysregulation of these enzymes was mainly observed in the ACC,
2 studies of PFC, and 2 studies of CC and TL.
Dysregulation of different ATP synthase subunits, such as
ATP5A1, ATP5B, and ATP5H in PFC, ACC, CC, TL, and
hippocampus suggests abnormalities of mitochondrial function.
Overall dysregulation of energy metabolism leads, among other
consequences, to overproduction of reactive oxygen species
(ROS) and oxidative stress. Oxidative stress events present
in schizophrenia and have been identified on a proteomic
level through dysregulation of several groups of enzymes,
mainly peroxiredoxins (PRDXs), glutathione transferases (GST),
NADPH-dependent oxidoreductases, and antioxidant enzymes.
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Themost prominent dysregulationwas observed at peroxiredoxins
(PRDX1, 2, 3, 6) found with differential abundancies in 11
proteomics studies and in all investigated brain regions except
MDT. Glutathione S-transferase P (GSTP1), carbonyl reductase
1 (CBR1), quinoid dihydropteridine reductase (QDPR), and
antioxidant enzyme superoxide dismutase (SOD1) were also
found with differential abundances in several studies and various
brain regions, but not in FC and PFC. From the proteins
involved in other energy pathways, vacuolar ATP synthases
(ATP6V1A, ATP6V1B2, ATP6V0A1) and creatine kinase (CKB)
were consistently found with differential abundance in all of the
investigated brain regions of schizophrenia patients. The rest
of the proteins from this group (glutamine synthase [GLUL],
transketolase [TKT], and carbonic anhydrase 1 and 2 [CA1/2])
were found with differential abundance in some brain regions, as
presented in Table 1.
As with the proteins involved in energy metabolism,
proteomics studies of the brain tissue consistently revealed
changes in the abundance of some of the cytoskeletal components
of the cell. These encompassed 4 major components: (1)
microfilaments composed of actin, (2) microtubules composed
of tubulin, (3) intermediate filaments, which are a family of
about 70 different proteins, and (4) microtubule associated
proteins. Differential abundance of beta and gamma actin
isoforms was observed in 8 studies, including three studies of
dorsolateral PFC, while the others included all other investigated
brain areas. Alpha and beta tubulins were also found with
differential abundance in 12 independent studies, mainly in
PFC, ACC, CC, and hippocampus. There were 5 intermediate
filament proteins with disturbed abundance in schizophrenia:
desmin (DES), vimentin (VIM), glial fibrillary acidic protein
(GFAP), and neurofilament medium and light chains (NEFM
andNEFL). Themost prominent change inivolved neurofilament
proteins, observed in 11 studies, followed by GAFP in
9 studies, and in all investigated brain regions. Disturbed
levels of VIM and DES were observed less frequently, in 5
(English et al., 2009; Martins-de-Souza et al., 2009c, 2010b;
Nesvaderani et al., 2009; Saia-Cereda et al., 2015) and 1 study
(Martins-de-Souza et al., 2009c), respectively. Microtubule-
associated proteins (MAPs) with differential abundance in
schizophrenia encompassed microtubule-associated proteins 1A
(MAP1A), 2 (MAP2), and tau (MAPT), and dynamin 1
(DNM1). The differential abundance of these proteins was
observed at lower rates than were other cytoskeletal proteins.
Changed levels of DNM1 were found in 5 studies of which
3 assayed PFC (Prabakaran et al., 2004; Pennington et al.,
2008; Martins-de-Souza et al., 2009a) and 2 assayed ACC
(Clark et al., 2006; Föcking et al., 2015), while MAP1A
and MAPT were found in only 2 studies, 1 of PFC (also
including MAP2) and 1 of MDT (Martins-de-Souza et al., 2009c,
2010b).
Cytoskeleton associated proteins dihydropyrimidinase-related
protein 2 (DPYSL2), 14-3-3 protein family (YWHAE, YWHAZ,
YWHAG, YWHAH, YWHAB), spectrin (SPTAN1), stathmin
(STMN1), and various representatives from the heat shock
proteins (HSPD1, HSPA5, HSPA8, HSPA1L, HSPA1A, HSPA1B)
were detected with abnormal abundance in more than 5
independent studies, providing further support for cytoskeletal
dysfunction in schizophrenia.
Oligodendrocyte dysfunction in schizophrenia has been
suggested by brain imaging, epigenetic and transcriptomics
studies, discussed in detail elsewhere (Dwork et al., 2007;
Martins-de-Souza, 2010; Haroutunian et al., 2014). Six proteomics
studies from 2 independent groups so far have found altered
expression of some of the oligodendrocyte-related proteins
in schizoprenia brain tissues such as 2′,3′-cyclic nucleotide
3′-phosphodiesterase (CNP), myelin basic protein (MBP),
myelin oligodendrocyte glycoprotein (MOG), and gelsolin (GSN;
Prabakaran et al., 2004; Martins-de-Souza et al., 2009a,c,d,
2010b; Saia-Cereda et al., 2015). We found 5 proteomics studies
focused on white matter. Three (Sivagnanasundaram et al.,
2007; Steiner et al., 2014; Saia-Cereda et al., 2015) examined
corpus callosum. One (Steiner et al., 2014) was focused on
S100B, reportedly elevated in blood and CSF of individuals
with schizophrenia, and found a decrease of 50–70% by mass
spectroscopy and western blot. The more recent (Saia-Cereda
et al., 2015) of the other two studies, employing label-free nano
LC/MS/MS, identified downregulation of CNP, MBP, MOG, and
GSN, while they were not found to be abnormal in the older
study (Sivagnanasundaram et al., 2007), which employed 2-
D PAGE/MS. Proteins involved in filaments and microtubules
were abundantly represented in the results from both studies,
although fiber densities in the corpus callosum have mostly
been found unaffected by schizophrenia (reviewed in Dwork
et al., 2007). The other two proteomics studies analyzed post
mortem white matter from PFC (English et al., 2009) and ACC
(Clark et al., 2007). Both found reduced levels of ALDOC in
schizophrenia. Among myelin-related proteins, the only change
in schizophrenia was upregulation of PLP1 in prefrontal white
matter. In contrast, in situ hybridization of ACC white matter
showed downregulation of mRNA for CNP and MAG in
schizophrenia (McCullumsmith et al., 2007). In a targeted study
(Dracheva et al., 2006), western blot for CNP showed decreased
levels in the hippocampus but not the putamen from individuals
with schizophrenia.
One study (Krishnamurthy et al., 2013; included in Table 2)
employed several platforms to study pituitary gland from
autopsies of individuals with schizophrenia or without psychiatric
illness. The pituitary glands from subjects with schizophrenia
showed disturbance in hypothalamic- pituitary-adrenal axis,
immune system, lipid transport, and metabolism. By LC-
MSE, prolactin was significantly lower, by approximately
35% in pituitary from chronically medicated individuals with
schizophrenia, suggesting that despite antipsychotic medication,
prolactin production was suppressed by elevated dopamine.
While the same average difference was found by western blot,
for schizophrenia and bipolar disorder as well, the differences
from normal were not significant. By contrast, western blot gave
virtually identical levels for follicle stimulating hormone across
all diagnostic groups.
Body Fluids Biomarkers
The comparative proteomics analysis of body fluids is of highest
clinical interest as it may reveal biomarkers for diagnosis,
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TABLE 2 | Candidate protein biomarkers for schizophrenia obtained by proteomics studies using human body fluids and tissues other than brain.
Number of
proteins with
altered
abundances
Body fluid Candidate biomarkers Processes and
pathways affected
Study design Method References
1 CSF APOA4↓ Reverse cholesterol
transport
10 controls and 10 schizophrenia
patients were pooled to form
four pools for each group
2-D
PAGE/MS
Jiang et al., 2003
2 CSF VGF 23-62 peptide↑; TTR↓ Synaptic plasticity,
penile erection,
circadian clock,
thyroid hormone
binding
58 schizophrenia, 16 with
depression, 5 with
obsessive-compulsive disorder,
10 with Alzheimer disease and
90 controls
SELDI-TOF-
MS
Huang et al., 2006
1 CSF APOA1↓ Plasma cholesterol
esters formation
CSF: 41 vs. 40; liver:15 vs. 15;
RBC: 20 vs. 20; serum: 35 vs.
63; brain 1st exp: 8 vs. 8; brain
2nd exp: 9 vs. 9
SELDI-TOF-
MS
Huang et al., 2008
6 CSF APOE↑; APOA1↑; TTR↓;
TGFBR1↓; CCDC3↓; PTGDS↑
Molecular transport,
signal transduction
receptors
17 first episode schizophrenia
and 10 controls
Western
blot
Martins-De-Souza
et al., 2010c
7 plasma HP↑; SERPINA1↑; CFB↑;
APOA1↓; APOA4↑; TTR↓
Acute phase proteins,
molecular transport
22 schizophrenia patients and 20
controls
2-D
PAGE/MS
Yang et al., 2006
6 plasma HP↑; SERPINA1↑; APCS↑;
AMBP↑; SERPINC1↑; GC↑
Acute phase,
coagulation and
transport
42 schizophrenia patients and 46
healthy controls
2-D
PAGE/MS
Wan et al., 2007
1 plasma α-defensins (DEFA) ↑ Dysregulation of
immune pathway of
peripheral white
blood cells
T cell lysates from 15
schizophrenia and 15 controls
SELDI-TOF-
MS
Craddock et al.,
2008
79 plasma BDNF↑; EGF↑; CXCL5↑;
TIMP1↑; MMP9↑; Insulin↑
Synaptic
transmission, growth
factors,
chemo-attractants,
proteolytic system
245 major depressive disorder,
229 schizophrenia and 254
controls
Multiplexed
immunoassay
Domenici et al.,
2010
10 serum CD5L↓; IGHM↓; F13B↓; TF↓;
AHSG↓; APOD↓; APOA1↓;
APOA4↓; APOA2↓; APOC1↓
Lipid metabolism,
cholesterol transport
pathway, immune
response
22 first onset schizophrenia
patients and 33 matched
controls
Label-free
nano
LC-MS/MS
(MSE)
Levin et al., 2010
181 tested serum 51 biomarker panel Diverse protein
functions
577 schizophrenia patients and
229 controls
Multiplexed
immunoassay
Schwarz et al.,
2010
21 tested (7
selected)
serum Insulin ↑; CHGA↑; PPY↑;
PRL↑; Cortisol↑; GH1↓;
Progesterone↑;prolactin↑
growth hormone↓
Dysregulation of
glucose metabolism,
hypothalamic-
pituitary-
adrenalgonadal axis
hormones
236 first and recent onset
schizophrenia patients and 230
matched controls
Multiplex
immunoassay;
2D-DIGE
Guest et al., 2011
181 tested serum 34 biomarker panel Diverse protein
functions
250 first and recent onset
schizophrenia, 35 major
depressive disorder, 32 bipolar
disorder, 45 Asperger syndrome
and 280 control subjects
Multiplexed
immunoassay
Schwarz et al.,
2012a
(Continued)
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TABLE 2 | Continued
Number of
proteins with
altered
abundances
Body fluid Candidate biomarkers Processes and
pathways affected
Study design Method References
20 serum SPP1↓; CALB1↑; CTGF↑;
TBG↑; APOA1↑; APOB↑;
CHGA↑; AMBP↓; IL6R↓; IL17↓;
CD5L↑; PROS1↑; APCS↑;
CA125↓; TFF3↓; GOT1↓; HGF↓
Inflammation and
immune response
75 schizophrenia, 110 bipolar
disorder patients and their
matched controls (75+110)
Multiplexed
immunoassay
Schwarz et al.,
2012b
191 tested serum Symptom severity (FABP5; CKB;
MB; CRP; MMP9; HGF)
Response prediction (insulin)
Time to relapse (LEP↓;
proinsulin ↓; TGFA↑; CD5L↓;
B2M↓; MMP9↑; CD40↓;
APOC1↓)
Acute phase
response pathway,
transport, immune
response, glucose
metabolic pathways
77 schizophrenia patients were
analyzed to identify molecules
associated with symptom
severity, predict response over a
6-week treatment period and
predict the time to relapse
Multiplexed
immunoassay
Schwarz et al.,
2012c
35 (additional
59 with only
phosporilation
pattern
changes)
serum Altered abundance and
phosphorylation: ALS2↑;
MAST1↑; CFB↑; C4BPA↑;
CFHR3↑; C6↑; ITIH3↑;
APOA1↓; MYOF↓; APOA2↓;
CCDC57↓; SMC1A↓; GPLD1↓
Acute phase
response signaling
pathway,
Complement system,
LXR/RXR activation,
Coagulation system,
Intristic prothrombin
activation pathway
20 antipsychotic-naïve
schizophrenia patients and 20
matched healthy controls
IMAC/LC-
MS/MS
(MSE)
Jaros et al., 2012
27 serum ANPEP↓; APOC2↓;APOF↓;
APOL1↓; C4BPB↓; C8B↑;
CD5L↑; DBH↑; F7↓; GGH↓;
ICAM2↓; IGFALS↓; IGHG4↑;
SERPINA5↑; IGHM↑; ITIH4↑;
KNG1↑; LBP↓; PGLYRP2↑;
PI16↑; PLTP↑; PROS1↓;
ZNF57↓
Complement system,
coagulation cascades
10 antipsychotic drug- naïve
schizophrenia patients and 10
healthy volunteers
LC-MS/MS Li et al., 2012
23 immune
molecules and
30 growth
factors and
hormones
serum group 1 (MIF, CXCL8, IL1RN,
IL18, and IL16)
group 2 (prolactin, resistin,
testosterone, insulin, PDGFRA,
LEPROT, and AGT)
Identified 2
subgroups of
schizophrenia
patients based on
molecular serum
profiles. Group 1 had
changes in immune
molecules, and group
2 changes in growth
factors and
hormones
180 antipsychotic-naive
schizophrenia patients and 398
matched controls
Multiplexed
immunoassay
Schwarz et al.,
2014
5 blood Insulin↑; proinsulin↑;
des-31,32-proinsulin↑;
C-peptide↑; CHGA↑
Dysregulation of
glucose metabolic
pathways
66 schizophrenia, 10 bipolar and
78 matched controls
Fluorescence
assays and
immunoassays
Guest et al., 2010
17 validated by
MRM/MS
sweat AZGP1↑; ANXA5↑; TXN↑;
ARG2↑; BLMH↑; CDSN↑;
CALML5↑; CASP14↑; CSTA↑;
DSG↑; PARK7↑; G3PDH↑;
KLK11↑; PSBP1↑; S100A7↑;
PRDX1↑; PIP↓
Oxidative stress, lipid
metabolism, Ca and
others binding
proteins, epidermal
differentiation and
integrity, proteinase
inhibitors, cell-cell
adhesion, glycolysis
The first set was made by
pooling of 8 patients samples
and 8 controls. The second set
was made by pooling of 4
patients and 4 controls
LC−MS/MS;
MRM/MS
Raiszadeh et al.,
2012
(Continued)
Frontiers in Cellular Neuroscience | www.frontiersin.org 11 February 2016 | Volume 10 | Article 18
Davalieva et al. Proteomics Research in Schizophrenia
TABLE 2 | Continued
Number of
proteins with
altered
abundances
Body fluid Candidate biomarkers Processes and
pathways affected
Study design Method References
8 saliva DEFA1-4↑; S100A12↑; CSTA↑;
S-derivatives of CSTB↑
Dysregulation of
immune pathway of
peripheral white
blood cells
32 schizophrenia, 17 bipolar and
31 healthy controls
RP-HPLC–
ESI-MS
(top-down)
Iavarone et al.,
2014
18 peripheral
blood
mononucl-
ear cells
(PBMCs)
Unstimulated PBMCs (CNDP2↑;
COTL1↓; GPI↓; HSPA2↓;
LDHB↑) Stimulated PBMCs
(ALDOC↑; HSPD1↓; GAPDH↑;
HNRPK↑; LDHB↑; NAMPT↑;
MYH14/15↑; PGK1↑; PPIA↑;
TPI1↑; PKLR↑; PGAM4↑)
Dysregulation of
glucolytic pathway
12 first onset schizophrenia
patients, 7 chronically ill
antipsychotic treated
schizophrenia patients and 19
healthy controls
Label-free
nano
LC-MS/MS
(MSE)
Herberth et al.,
2011
29 (LC-MSE) 13
(2-D DIGE)
pituitary
gland
LC-MSE (SIPA1↑; CEMIP↑;
FGB↑; CFAP43↑; MYH9↑;
HNRNPA2B↓TTC28↓; PIWIL3↓;
APOA1↓; APOA2↓; CKB↓;
TUBA1A↓; TUBB1B↓;
TUBB2C↓; AHSG↓; TGM2↓;
TUBB4B↓; LMX1B↓; CTNND2↓;
YWHAQ↓; HP↓; CRYM↓;
HSPB1↓; SCGN↓; SETD5↓;
TIAM2↓;
Disturbance in
hypothalamic—
pituitary—adrenal
axis, immune system,
lipid transport and
metabolism
14 schizophrenia and 15 control
subjects were analyzed by
comparative proteomics.
Additional 13 bipolar disorder
and 14 major depression
patients were included in
Western validation
LC-MS/MS
(MSE)
Multiplexed
immunoassay,
2-D DIGE,
Western
blot
Krishnamurthy
et al., 2013
Candidate biomarkers found in more than one independent study are highlighted in bold. The arrows indicate the increase (↑) or decrease (↓) of the protein level in schizophrenia group
compared to control group(s).
choice of therapy and future course of schizophrenia. We found
20 proteomics studies investigating potential schizophrenia
biomarkers in cerebrospinal fluid, blood, sweat, and saliva, and
2 additional studies investigating protein alterations in peripheral
blood mononuclear cells (PBMCs) and the aforementioned study
of pituitary gland (Table 2).
Cerebrospinal fluid (CSF) and blood are the main body
fluids used in proteomic studies of neurological or psychiatric
disorders, including schizophrenia. CSF is presumed to be
representative of the extracellular space in the CNS. Consequently,
pathological abnormalities of the brainmight be directly reflected
in CSF. Normal CSF protein concentrations are ∼0.5% those of
normal serum or plasma, requiring highly sensitive analytical
techniques. Fewer proteins can normally be detected. CSF
sampling is moderately invasive, so it is difficult to perform
longitudinal studies. The first 2-D map of human CSF proteome
was presented by Goldman and collaborators in 1980 (Goldman
et al., 1980). With the development of proteomics technologies,
different approaches were used for discovering CSF biomarkers
for schizophrenia: 2-D PAGE and 2-D DIGE followed by
MALDI-MS identification (Jiang et al., 2003; Martins-De-Souza
et al., 2010c) and SELDI-MS (Huang et al., 2006, 2008).
These studies revealed altered levels of proteins involved in
molecular transport of cholesterol and of proteins involved
in phospholipid metabolism [apolipoprotein A-I (APOA1),
apolipoprotein A-IV (APOA4), and apolipoprotein E (APOE),
23-62 VGF peptide], transthyretin (TTR), arachidonic acid
metabolism enzyme-prostaglandin-H2 D-isomerase (PTGDS),
coiled-coil domain-containing protein 3 precursor (CCDC3),
and transforming growth factor-β receptor type-1 (TGFBR1).
The major advantage of using blood for biomarker discovery
arises from two main blood characteristics. With the exception of
the urine, which usually contains no protein, blood is the most
easily and least invasively sampled body fluid for clinical studies.
This accessibility allows multiple samplings at various stages of
the disease and treatment. Second, blood interacts with all tissues,
and therefore can indicate changes anywhere in the body.
We found 14 proteomic studies investigating potential
biomarkers in plasma and serum. The first 2 studies investigated
the plasma proteome by 2-D PAGE coupled with MS.
They revealed altered levels of acute phase response proteins
(Yang et al., 2006; Wan et al., 2007), suggesting a link
between inflammatory response systems and pathophysiology of
schizophrenia. The affected proteins included haptoglobin (HP),
α-1-antitrypsin (SERPINA1), complement factor B precursor
(CFB), apolipoprotein A1 (APOA1), apolipoprotein A4 (APOA4),
transthyretin (TTR), serum amyloid P-component (APCS),
alpha-1-microglobulin (AMBP), and antithrombin III (SERPINC1).
A study using a SELDI-TOF platform to analyze lysates
of stimulated T lymphocytes found alterations of α-defensin
(DEFA) in minimally medicated subjects with schizophrenia,
and also in their monozygotic twins without schizophrenia
(Craddock et al., 2008), suggesting a marker for
susceptibility.
There are 3 studies of serum proteome so far using label-free
LC-MS/MS. The first study of serum proteome found that the
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most significantly changed proteins belong to the apolipoprotein
family (apolipoprotein D [APOD], apolipoprotein A1 [APOA1],
apolipoprotein A4 [APOA4], apolipoprotein A2 [APOA2], and
apolipoprotein C1 [APOC1]), involved in the metabolism of
high-density lipoprotein and triglyceride-rich lipoproteins, and
in the reverse cholesterol transport pathway. These were followed
by proteins involved in immune response (CD5 molecule-like
[CD5L], IgM [IGHM], transferrin [TF]) and in insulin resistance
(α-2-HS glycoprotein [AHSG]; Levin et al., 2010). Subsequent
studies (Jaros et al., 2012; Li et al., 2012) confirmed that subjects
with schizophrenia feature serum abnormalities in levels and
phosphorylation of proteins involved in immune response. These
studies also implicated the complement and coagulation cascades
as the most significant pathways disturbed in schizophrenia.
However, the majority of the studies on plasma and serum
have usedmultiplexed immunoassays containing selected subsets
of biomarkers, constructed based on the findings from previous
discovery proteomics studies. The first attempt to develop a
molecular test with clinical utility for diagnosis of schizophrenia
resulted in formation of a 51-plex biomarker panel with
sensitivity and specificity of 83% (Schwarz et al., 2010). The
study of specificity of this panel for schizophrenia compared
with other psychiatric disorders led to establishment of a
reduced, 34-biomarker panel that gave a separation of 60–75%
of schizophrenia subjects from controls across 5 independent
cohorts (Schwarz et al., 2012a). In the most recent studies,
the multiplexed immunoassay test was also investigated for the
ability to identify the disease prior to clinical manifestation
(Schwarz et al., 2012b) and to characterize subgroups of
individuals with schizophrenia on the basis of the molecular
pathways affected (Schwarz et al., 2014).
Several multiplex immunoassay studies identified elevated
insulin-related peptides in untreated first-onset schizophrenia
subjects, suggesting that dysregulation of glucose metabolic
pathways may have a role in the development of schizophrenia
(Guest et al., 2010, 2011; Schwarz et al., 2012c). Immune response
alterations have also been observed by several studies (Schwarz
et al., 2012b,c). Also, altered levels of hormones (prolactin,
cortisol, progesterone, and growth hormone) in blood have been
observed in people with schizophrenia, indicating that functions
of multiple components of the hypothalamic-pituitary-adrenal-
gonadal axis may be affected (Domenici et al., 2010; Guest et al.,
2011).
There is only one report describing sweat proteome alteration
in schizophrenia (Raiszadeh et al., 2012). The eccrine sweat
glands, controlled by the sympathetic nervous system, are
responsible for thermoregulation. Distributed over the entire
body, they produce a fluid that is composed of inorganic ions,
lactate, urea, ammonia, amino acids, and proteins, including
plasma and epidermal proteins. The study of Raiszadeh et al.
(2012) revealed 17 proteins with differential abundance of
approximately two-fold or greater between schizophrenia and
healthy subjects (listed inTable 2). These proteins involve diverse
biological functions: oxidative stress, lipid metabolism, calcium-
binding and other binding proteins, epidermal differentiation
and integrity, protease inhibition, cell-cell adhesion, and
glycolysis. The potential of sweat as a source for new
schizophrenia biomarkers was highlighted, since only 5 proteins
[albumin (ALB), alpha-2-glycoprotein 1 (AZGP1), clusterin
isoform 1 (CLU), apolipoprotein D precursor (APOD), and
gelsolin isoform b (GSN)] were found in common between sweat
and serum.
Saliva allows non-invasive specimen collection, and it can
sometimes be a good substitute for plasma or blood. Until now,
only one study has investigated saliva as a potential source for
schizophrenia and bipolar disease biomarkers using top down
proteomics platform (RP-HPLC–ESI-MS; Iavarone et al., 2014).
All significantly altered proteins and peptides were involved in
innate immunity (α-defensins 1–4, S100A12, cystatin A and
S-derivatives of cystatin B). However, as increased levels of these
proteins were also found in association with neoplasms and
infectious diseases, the authors concluded that this set of proteins
has low diagnostic potential for schizophrenia.
One small study (Herberth et al., 2011) used LC-MSE to
investigate the proteomes of PBMCs, at baseline and after
72 h of stimulation by staphylococcal enterotoxin and CD28.
Cells from antipsychotic-naïve subjects in the first episode
of schizophrenia, compared with cells from healthy subjects,
showed altered levels of some glycolytic enzymes at rest, and
more after stimulation, while these alterations were not seen
in PBMC from individuals with chronic schizophrenia and
antipsychotic treatment. Curiously, the post-stimulation levels
of ALDOC were greater in the cells from anti-psychotic-naïve
schizophrenia subjects than in the cells from healthy subjects,
while there was no reported abnormality of ALDOA, which in
PBMC is an order of magnitude more abundant than ALDOC,
and two orders of magnitude more abundant than ALDOB (see:
http://moped.proteinspire.org/; Kim et al., 2014; Montague et al.,
2015). As discussed elsewhere in this review, in schizophrenia,
ALDOC is the most frequently abnormally-expressed protein
identified in proteomic studies of the brain, where its expression
is predominantly astrocytic, but some studies of schizophrenia
find elevated levels and others find depressed levels (see below
and Tables 1, 5). An abnormal response of the C isoform in a cell
that normally expresses predominantly the A isoform could point
to a specific dysregulation of the C isoform in schizophrenia, but
it could also indicate a general lability of the C isoform in the
presence of independent abnormalities of glycolysis.
THE SPECIFICITY OF THE CANDIDATE
BIOMARKERS FOR SCHIZOPHRENIA
To evaluate the overlap of the schizophrenia-associated candidate
biomarkers with candidate biomarkers for other neurological
diseases, we reviewed proteomic studies and reviews of several
diseases such as bipolar disorder, major depressive disorder,
Alzheimer’s disease and Parkinson’s disease.
We found 5 proteomics studies where both schizophrenia and
bipolar disorder were compared with a non-psychiatric group
(Novikova et al., 2006; Pennington et al., 2008; Behan et al.,
2009; English et al., 2009; Föcking et al., 2011). Pennington
et al. (2008) found 6 out of 66 proteins to be altered in both
diseases, with cytoskeleton and synaptic-associated function (two
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forms of SEPT5, SEPT11, DPYSL3, TCP1), metabolism and
CNS development (PHGDH). However, half of the proteins
with altered abundance in bipolar disorder were cytoskeletal,
metabolic or mitochondrial-associated proteins and some, such
as TUBA, TUBB, NEFM, ATP5B, ENO2, PRDX2, PRDX6,
ATP6V1A have been frequently found in schizophrenia studies
(Table 1). Behan et al. (2009) identified three proteins involved
in synapse-associated functions (LSAMP, BASP1, and STXBP1)
while in a subsequent study from the same group (English
et al., 2009), some intermediate filaments (NEFH, vimentin) and
cytoskeleton-associated proteins (DPYSL2, DPYSL3, YWHAE)
showed the same change in abundance in bipolar disorder as
in schizophrenia. Novikova et al. (2006) found 5 proteins that
were altered in both schizophrenia and bipolar disorder (CEBPZ,
DECR2, BYSL, ANKARD, and ALDOC), associated with cell
signaling, lipid and glucose metabolism, and other intracellular
processes. The comparative proteomic analysis of hippocampus
reported similar protein changes in schizophrenia and bipolar
disorder with two-thirds of the proteins with altered abundances
in schizophrenia showing the same trend in bipolar disorder as
well (Föcking et al., 2011). These proteins were mostly involved
in cytoskeletal and metabolic cellular mechanisms.
Two proteomic studies included major depressive disorder
(MDD) in addition to schizophrenia and bipolar disorder. In
one of the first proteomics studies of the brain, abundance of
3 proteins (DPYSL2, ALDOC, and GFAP) were altered in the
frontal cortex in all three disorders (Johnston-Wilson et al.,
2000). Altered levels of these proteins, associated with synaptic
function, glycolysis, and cytoskeletal structure, respectively, were
subsequently confirmed by most other proteomic studies of the
brain in schizophrenia. A study of the protein changes in ACC in
schizophrenia, MDD and bipolar disorder found that cytoskeletal
and mitochondrial proteins are the most prominently altered
in all of these disorders, but only 2 identified proteins (SRI,
ALDOC) were found with changed levels in both schizophrenia
and MDD (Beasley et al., 2006). The rest of the MDD -
focused studies identified candidate biomarkers that to some
extent overlap with those for schizophrenia (Martins-de-Souza,
2014). The biological functions implicated in MDD, such as
energy metabolism, cellular transport, and cell communication
and signaling are also the main pathways implicated in
schizophrenia. However, several important differences that help
in differentiation of these diseases on a protein level were
observed: The disorders were associated with different pathways
of energy metabolism (glycolysis is the main affected pathway in
schizophrenia, while oxidative phosphorylation is more affected
in MDD) and opposite changes of the same proteins were
identified in both diseases (Martins-de-Souza et al., 2012a).
From the 93 proteins that have shown quantitative changes
or modifications in 43 2-D based proteomic studies in 13
different brain regions in Alzheimer’s disease between 1999 and
2010 (Korolainen et al., 2010), 34 proteins have been reported
in schizophrenia brain proteomics studies as well. These 34
proteins point to the same disturbances in two major pathways:
One is energy metabolism, especially glycolysis (ALDOA/C,
ENO1/2, GAPDH, LDHB, PGAM1, PKM2, TPI1), Krebs cycle
(ACO2,MDH1), mitochondrial function (ATP5A1, ATP5B), and
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oxidative stress (Piredoxins [PRDX2, 3, 6], SOD, CKB). The other
pathway is cytoskeletal, through tubulins (TUBA1B, TUBA1C,
TUBB), intermediate filaments (GFAP, NEFL,) cytoskeleton
associated proteins (DPYSL2, YWHAE, YWHAG, STMN1,) and
heat shock proteins (HSPA9, HSPA5, HSPD1, HSPA1A, HSPA2,
HSPA8). Although the comparative proteomics studies of post-
mortem human brains from Parkinson’s disease are quite limited,
the reported proteins showed some overlap with schizophrenia
in neurofilaments (NEFL, NEFM), peroxiredoxins, and proteins
involved in ATP synthesis (Srivastava et al., 2010).
The majority of the blood-based candidate proteins for
schizophrenia are also involved in Parkinson’s disease, Alzheimer’s
disease, and MDD. Several acute phase proteins (A2M, C3,
SERPINA1, and ALB), proposed as candidate biomarkers for
schizophrenia, were also found to be associated with Parkinson’s
disease, Alzheimer’s disease, and MDD (Chiam et al., 2015). In
addition, APOE and APCS were associated with both Parkinson’s
disease and Alzheimer’s disease.
From the proposed candidate cerebrospinal fluid biomarkers
for schizophrenia (Table 2), APOA1, APOA4, APOE, and
PTGDS have been also proposed as candidate biomarkers for
Alzheimer’s disease and TTR (synthesized in the brain uniquely
by choroid plexus, Herbert et al., 1986) as a candidate biomarker
for Parkinson’s and Alzheimer’s diseases (Korolainen et al., 2010;
Kroksveen et al., 2011).
CELL-SPECIFIC PROTEINS
Since different cells produce different proteins, one could look
to proteomics for evidence of specific cell types affected in
schizophrenia. We therefore compared the proteins in Table 1
with lists of genes identified in a large study of transcriptional
signatures of cell type in mouse CNS (Cahoy et al., 2008) and a
comparison of microglia with circulating monocytes (Yamasaki
et al., 2014). From the former report, we extracted 240 genes,
of which 106 were preferentially expressed in astrocytes, 83
in oligodendrocytes, 43 in neurons, 5 in endothelial cells, and
3 in microglia. From the latter, we extracted 76 genes, of
which 48 were preferentially expressed in microglia and 28
in monocytes. Of the 221 proteins reported as differentially
expressed in schizophrenia (Table 1), mRNA sequences for 22
were also reported as characteristic of individual cell types
(Table 3). These include the 2 proteins most frequently reported
altered in schizophrenia, ALDOC (11 reports) and GFAP (9
reports), both expressed predominantly in astrocytes.
For a more inclusive analysis, we made use of a published
dataset (http://jiaqianwulab.org/resource.htm) frommouse RNA
sequencing (RNAseq) expriments (Zhang et al., 2014; Dong et al.,
2015). This dataset includes expression levels of 22,462 genes
from neurons (NEU), astrocytes (ASTRO), endothelial cells
(ENDO), microglia (MGL), myelinating oligodendrocytes (MO),
newly formed oligodendrocytes (NFO), and oligodendrocyte
precursor cells (OPC). Expression levels in different cell types
were highly correlated (Figure 1A), so gene expression in two
cell types can be compared, and genes enriched in either cell
type, relative to the other, can be determined by linear regression
(e.g., Figure 1B). Similarly, one cell type can be compared with
TABLE 4 | Oligodendroglial proteins most commonly cited.
Region MBP CNP MOG GSN References
BA9 gray and
white matter
↓ ↓ Prabakaran et al., 2004
BA46 ↓ ↓ Martins-de-Souza et al., 2009c
Corpus callosum ↓ ↓ ↓ ↓ Saia-Cereda et al., 2015
BA38, left ↓ ↓ ↓ Martins-de-Souza et al., 2009d
BA46, left ↓ Martins-de-Souza et al., 2009a
Hippocampus ↑ Nesvaderani et al., 2009
Mediodorsal
thalamus
↑ Martins-de-Souza et al., 2010a
Proteomics studies of brain reporting altered levels of myelin-associated proteins MBP,
CNP, MOG, or GSN. Arrows as in Table 1.
TABLE 5 | Astrocytic proteins most commonly cited.
Schizophrenia relative to nonpsychiatric GFAP
Higher Lower Neither Total
ALDOC Higher 1 1 2 4
Lower 1 2 4 7
Neither 2 2 4
Total 4 5 6 15
Numbers of studies from Table 1 reporting differences between schizophrenia and
non-psychiatric cases in GFAP, ALDOC, or both. Since most reports do not include
tabulations of all identified proteins, the category of “Neither” higher nor lower does not
distinguish failure to identify the protein and a failure to find a significant difference between
schizophrenia and non-psychiatric cases.
several others simultaneously by performing multiple linear
regression and identifying the genes with standardized residuals
greater than 2 (Figure 1C). By regression of each of 6 brain
cell types against the others we found 714 such genes, of which
78 code for proteins that proteomic studies have identified as
affected in schizophrenia. These include 7 of 14 genes expressed
preferentially in MO, 13/174 in ASTRO, 9/108 in OPC, 54/362
in NEU, 2/129 in ENDO, and 6/46 in MGL (Figure 2). These
regressions are restricted to comparisons amongst different types
of brain cells; they do not imply any comparison with expression
of transcripts in other organs.
The comparisons among cell types are based on RNA, which
does not necessarily correlate with levels of the encoded protein.
Furthermore, they are based on cells from mice, not humans.
However, the specificities (at least within the brain) of the
most commonly cited astrocytic proteins, ALDOC and GFAP
are well-established by immunohistochemistry on the human
brain [except for the presence of ALDOC in cerebellar Purkinje
cells (Thompson et al., 1982; Kumanishi et al., 1985), which
were not included in any of the proteomic studies]. Similarly,
the specificities of the most commonly cited oligodendroglial
proteins, MBP, CNP, MOG, and GSN (Tanaka and Sobue,
1994), all associated with myelin, are also well-established by
immunohistochemistry.
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Pearson's r nfo opc neu endo astro mgl
mo 0.958 0.060 0.034 0.031 0.016 0.018
nfo 0.112 0.111 0.058 0.056 0.032
opc 0.578 0.524 0.392 0.342
neu 0.417 0.366 0.167
endo 0.176 0.159
astro 0.451
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FIGURE 1 | Analysis of mouse RNAseq data from http://jiaqianwulab.org/resource.htm (Zhang et al., 2014; Dong et al., 2015). (A) Correlation coefficients
between cell types for all genes. (B) Linear regression of gene expression in ASTRO and NEU. Genes for proteins included in Table 1 are represented by red circles
and labeled where space permits. Other genes are represented by blue circles. Center line represents best fit and outer lines 95% confidence limits after log
transformation of data. (C) Multiple regression of ASTRO against other cell types. Linear regression of untransformed expression data for ASTRO against data for MO,
OPC, NEU, and ENDO, was performed, and standardized residuals were computed. NFO were omitted from all multiple correlations because of their very high
correlation with MO. Standardized residuals are potted on X-axis. The Y axis represents the ratio between expression level in ASTRO and the average expression
levels in the other five cell types. Genes with standardized residual values above two (i.e., to the right of the vertical line) were considered enriched in astrocytes.
Colors are as in (B); both red and blue circles are labeled where space permits.
CONCLUSION AND FUTURE
PERSPECTIVES IN SCHIZOPHRENIA
PROTEOMICS RESEARCH
We have attempted to review all studies of schizophrenia by
proteomics, including studies of autopsy brain tissues and bodily
fluids. The data lead us to conclude that there are important
issues regarding the proteomics platforms and samples that
make comparisons across studies quite difficult, especially when
different platforms are used. More comparisons with other
psychiatric illnesses are needed to address specificity. Proteomic
studies have been confined to a small number of brain regions,
with little attention to white matter.
Overall, however, the data from brain tissue point to
prominent changes in metabolic pathways and cytoskeleton.
The majority of studies of bodily fluids point toward immune
response, lipidmetabolism and to a lesser extent, dysregulation of
glucosemetabolic pathways. The discrepancy between findings in
tissue and body fluids has been observed generally in biomarker
studies, particularly in studies of cancer (Hanash et al., 2008).
This lack of tissue biomarker detection in the circulation may
be caused by low levels of release of disease-associated proteins
from tissues to body fluids, where they are susceptible to masking
by highly abundant blood proteins. Alternatively, circulating
proteins associated with a particular disease may be too dilute for
detection by the methods used for proteomics.
The comparison of the candidate biomarkers for schizophrenia
with candidate biomarkers for other neurological diseases,
such as bipolar disorder, MDD, Alzheimer’s disease, and
Parkinson’s disease reveal overlap. This could be due to common
disturbances in energy pathways and cytoskeletal function, or to
bias associated with the proteomics method used. Most of the
proteomics studies of brain tissues reviewed here and most of the
proteomics studies of common neurological disorders, reviewed
extensively elsewhere (Korolainen et al., 2010; Srivastava et al.,
2010), have been based on2-D gel-based platforms. This
approach is known to resolve only a limited collection of highly
abundant and soluble proteins (Petrak et al., 2008; Wang et al.,
2009). These proteins are mainly involved in central metabolism,
protein production (e.g., ribosomal proteins, some RNA binding
proteins, translation factors), protein conformational control
and degradation (chaperones, disulfide isomerases, proline
isomerases, proteasome subunits), cytoskeleton (including some
cytoskeleton modifying proteins), adaptor proteins (14-3-3,
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FIGURE 2 | Multiple regression was performed and plotted as in Figure 1C, except that only data points with standardized residuals >2 are shown. The
color of the symbols represents the number of proteomic studies in which the level of each protein was found differentially expressed in brain tissue from individuals
with schizophrenia (Table 1). Only genes for proteins cited at least once are labeled. Because of their biological relationship, MO expression was not included as an
independent variable in the regression of OPC, and OPC was not included in the regression of MO.
annexins), and oxidative stress response (catalase, superoxide
dismutases, peroxiredoxins, glutathione transferases). This limited
scope of 2-D gels might explain why so many so called
“specific” markers of various neurological diseases belong to the
same classes. However, the research using shotgun label-free
approaches, in comparative brain studies with MDD, provides
a more detailed and specific overview of the energy metabolism
pathways involved in the disease, with clues that these pathways
are different from those implicated in schizophrenia (Martins-de-
Souza et al., 2012a). Quantitative shotgun proteomics with data-
independent acquisition (MSE) coupled with wave ion mobility
has been applied to a wide variety of samples including cells,
tissues, clinical samples, and affinity pull downs, with power and
effectiveness firmly established and extensively validated bymany
independent groups (Brown, 2014). Therefore, future extensive
studies using proteomics platforms with wider dynamic range,
such as label-free data-independent (MSE) shotgun approach or
MALDI MSI combined with high resolution top-down tandem
MS identification could provide a more specific picture of the
affected pathways in schizophrenia.
Assessment of the cell specificity of candidate biomarkers
for schizophrenia did not point to exclusive dysfunction of
one specific brain cell type. However, transcripts for 35%
(78/221) of the proteins reported as affected in schizophrenia
are enriched in one or more cell types in mouse brain. Since
the vast majority (>95%) of mouse genes are not selectively
expressed in any one type of brain cell compared with the others,
there is clearly a preferential involvement of genes selectively
expressed by specific types of brain cells. Among these 78
proteins, twice as many are highly expressed in neurons as in
glia, but the glial proteins are found more consistently. Overall,
∼50% of citations are to proteins not specifically expressed by
individual types of brain cells, 30% to proteins preferentially
expressed by neurons, and 20% to proteins predominantly
expressed by glia. The most frequently referenced proteins are
ALDOC (astrocytic), followed by GFAP (astrocytic) and DPYSL2
(nonspecific), followed by NEFL (nonspecific) and then CKB
(oligodendroglial precursor and astrocytic). It is important to
remember that the expression profiles on which this analysis
relies are based solely on mRNA in mouse brain cells, since
Frontiers in Cellular Neuroscience | www.frontiersin.org 18 February 2016 | Volume 10 | Article 18
Davalieva et al. Proteomics Research in Schizophrenia
quantitative data on proteins in individual cell types from human
brain are not available.
Studies of white matter, which is nearly devoid of neuronal
cell bodies but abundantly, populated with oligodendroglia,
oligodendroglial precursor (NG2) cells, astrocytes, and microglia
showed some abnormalities of oligiodendroglial protein levels,
with considerable variation across studies, and little or no
replication ofmore consistent deficits in oligodendroglial mRNA.
Abnormal content of astrocytic proteins in white matter was
somewhat more consistent, with two studies reporting altered
levels of ALDOC, and one reporting abnormal levels of GFAP.
However, the picture changes somewhat when one looks beyond
the handful of studies restricted to white matter. Gray matter
includes myelin and all types of glia, and cortical samples cut
macroscopically from frozen brain slices will almost inevitably
include some white matter, intentionally or otherwise, since
the cortex curves in 3 dimensions. The 7 studies reporting
alterations in MBP, MOG, CNP, or GSN are listed in Table 4.
In schizophrenia, levels of all 4 were depressed in 1 study
of corpus callosum, while the 4 studies of neocortex found
depressions of 1, 2, 2, and 3 of the proteins, respectively, with
none elevated. Two studies, one of hippocampus and one of
thalamus, reported elevation of GSN and MOG, respectively.
Overall, these results corroborate the numerous reports from
RNA and targeted protein studies of myelin-related deficits in
schizophrenia. By contrast, while abnormalities of the astrocytic
proteins ALDOC and GFAP are the most frequently reported,
both are up in some studies and down in others, concordantly
in some studies and discordantly in others (Table 5). There
are many possible explanations, which must include the
very varied functions of astrocytes in healthy and diseased
brains.
At this time, exhaustive proteomic studies are new, and their
interpretation is far from straightforward. This difficulty would
be alleviated if researchers published entire datasets, rather than
just positive findings. This is especially important for proteomics
because, in contrast to mRNA expression studies, the total set
of identified proteins varies dramatically between studies, so
that proteins that are affected by disease in one study may
not be detected at all in another. The potentially confounding
influence of pre- and postmortem factors such as tissue pH,
postmortem interval, medication exposure, and in particular,
agonal state must always be reported and considered. Detailed
and complete clinical and demographic data should also be
included. Discovery proteomic studies, using well-matched sub-
pools of disease and control subjects, should be followed by
validation of important findings with other methods in larger
samples, not just in those employed for discovery. Overall,
the proteomics studies of schizophrenia so far have paved
the way for future research that should contribute to greater
understanding of the molecular mechanisms of the disease and
identify biomarkers for clear and effective diagnosis, nosology,
prognosis, and therapy. This is possible by using well-defined
samples, larger cohorts, combinations of proteomics techniques
to overcome limitations associated with individual techniques,
and extensive validation.
AUTHOR CONTRIBUTIONS
KD collected literature, assembled Tables 1 and 2, wrote the
first draft of the manuscript, and edited subsequent drafts. IM
collected literature, assembled Tables 1 and 2, and edited the
manuscript. AJD outlined the project, compared the human and
mouse data, prepared the figures and Tables 3–5, and revised and
edited the manuscript.
FUNDING
This study was supported by NIH Research Grants R01
MH098786, funded by the Fogarty International Center and the
National Institute of Mental Health, and R01 MH064168, funded
by the National Institute of Mental Health.
REFERENCES
Albus, M. (2012). Clinical courses of schizophrenia. Pharmacopsychiatry 45(Suppl.
1), S31–S35. doi: 10.1055/s-0032-1308968
Baggerly, K. A., Morris, J. S., and Coombes, K. R. (2004). Reproducibility of SELDI-
TOF protein patterns in serum: comparing datasets from different experiments.
Bioinformatics 20, 777–785. doi: 10.1093/bioinformatics/btg484
Beasley, C. L., Pennington, K., Behan, A., Wait, R., Dunn, M. J., and Cotter,
D. (2006). Proteomic analysis of the anterior cingulate cortex in the major
psychiatric disorders: evidence for disease-associated changes. Proteomics 6,
3414–3425. doi: 10.1002/pmic.200500069
Behan, A. T., Byrne, C., Dunn, M. J., Cagney, G., and Cotter, D. R. (2009).
Proteomic analysis of membrane microdomain-associated proteins in the
dorsolateral prefrontal cortex in schizophrenia and bipolar disorder reveals
alterations in LAMP, STXBP1 and BASP1 protein expression. Mol. Psychiatry
14, 601–613. doi: 10.1038/mp.2008.7
Benes, F. M., Vincent, S. L., and Todtenkopf, M. (2001). The density of pyramidal
and nonpyramidal neurons in anterior cingulate cortex of schizophrenic
and bipolar subjects. Biol. Psychiatry 50, 395–406. doi: 10.1016/S0006-
3223(01)01084-8
Bouras, C., Kövari, E., Hof, P. R., Riederer, B. M., and Giannakopoulos, P. (2001).
Anterior cingulate cortex pathology in schizophrenia and bipolar disorder.Acta
Neuropathol. 102, 373–379. doi: 10.1007/s004010100392
Brown, L. M. (2014). Quantitative shotgun proteomics with data-independent
acquisition and traveling wave ion mobility spectrometry: a versatile tool in the
life sciences. Adv. Exp. Med. Biol. 806, 79–91. doi: 10.1007/978-3-319-06068-
2_4
Butt, R. H., and Coorssen, J. R. (2005). Postfractionation for enhanced proteomic
analyses: routine electrophoretic methods increase the resolution of standard
2D-PAGE. J. Proteome Res. 4, 982–991. doi: 10.1021/pr050054d
Cahoy, J. D., Emery, B., Kaushal, A., Foo, L. C., Zamanian, J. L., Christopherson,
K. S., et al. (2008). A transcriptome database for astrocytes, neurons, and
oligodendrocytes: a new resource for understanding brain development
and function. J. Neurosci. 28, 264–278. doi: 10.1523/JNEUROSCI.4178-
07.2008
Carter, C. S., Mintun, M., Nichols, T., and Cohen, J. D. (1997). Anterior cingulate
gyrus dysfunction and selective attention deficits in schizophrenia: [15O]H2O
PET study during single-trial Stroop task performance. Am. J. Psychiatry 154,
1670–1675. doi: 10.1176/ajp.154.12.1670
Chana, G., Landau, S., Beasley, C., Everall, I. P., and Cotter, D. (2003). Two-
dimensional assessment of cytoarchitecture in the anterior cingulate cortex in
major depressive disorder, bipolar disorder, and schizophrenia: evidence for
decreased neuronal somal size and increased neuronal density. Biol. Psychiatry
53, 1086–1098. doi: 10.1016/s0006-3223(03)00114-8
Chiam, J. T., Dobson, R. J., Kiddle, S. J., and Sattlecker, M. (2015). Are blood-
based protein biomarkers for Alzheimer’s disease also involved in other
Frontiers in Cellular Neuroscience | www.frontiersin.org 19 February 2016 | Volume 10 | Article 18
Davalieva et al. Proteomics Research in Schizophrenia
brain disorders? A systematic review. J. Alzheimers. Dis. 43, 303–314. doi:
10.3233/JAD-140816
Clark, D., Dedova, I., Cordwell, S., and Matsumoto, I. (2006). A proteome analysis
of the anterior cingulate cortex gray matter in schizophrenia. Mol. Psychiatry
11, 459–470. doi: 10.1038/sj.mp.4001806
Clark, D., Dedova, I., Cordwell, S., and Matsumoto, I. (2007). Altered proteins
of the anterior cingulate cortex white matter proteome in schizophrenia.
Proteomics Clin. Appl. 1, 157–166. doi: 10.1002/prca.200600541
Cleghorn, J. M., Garnett, E. S., Nahmias, C., Brown, G. M., Kaplan, R. D.,
Szechtman, H., et al. (1990). Regional brain metabolism during auditory
hallucinations in chronic schizophrenia. Br. J. Psychiatry 157, 562–570. doi:
10.1192/bjp.157.4.562
Craddock, R. M., Huang, J. T., Jackson, E., Harris, N., Torrey, E. F., Herberth, M.,
et al. (2008). Increased alpha-defensins as a blood marker for schizophrenia
susceptibility.Mol. Cell. Proteomics 7, 1204–1213. doi: 10.1074/mcp.M700459-
MCP200
Daniel, D. G., Weinberger, D. R., Jones, D.W., Zigun, J. R., Coppola, R., Handel, S.,
et al. (1991). The effect of amphetamine on regional cerebral blood flow during
cognitive activation in schizophrenia. J. Neurosci. 11, 1907–1917.
Doerr, A., Finkelstein, J., Jarchum, I., Goodman, C., and Dekker, B. (2015). Nature
milestones: mass spectrometry. Nat. Methods 12, S1–S46.
Domenici, E., Wille, D. R., Tozzi, F., Prokopenko, I., Miller, S., McKeown, A.,
et al. (2010). Plasma protein biomarkers for depression and schizophrenia by
multi analyte profiling of case-control collections. PLoS ONE 5:e9166. doi:
10.1371/journal.pone.0009166
Domon, B., and Aebersold, R. (2006). Mass spectrometry and protein analysis.
Science 312, 212–217. doi: 10.1126/science.1124619
Dong, X., You, Y., and Wu, J. Q. (2015). Building an RNA sequencing
transcriptome of the central nervous system. Neuroscientist. doi:
10.1177/1073858415610541. [Epub ahead of print].
Dracheva, S., Davis, K. L., Chin, B.,Woo, D. A., Schmeidler, J., andHaroutunian, V.
(2006). Myelin-associatedmRNA and protein expression deficits in the anterior
cingulate cortex and hippocampus in elderly schizophrenia patients.Neurobiol.
Dis. 21, 531–540. doi: 10.1016/j.nbd.2005.08.012
Dwork, A. J. (1997). Postmortem studies of the hippocampal formation in
schizophrenia. Schizophr. Bull. 23, 385–402. doi: 10.1093/schbul/23.3.385
Dwork, A. J., Mancevski, B., and Rosoklija, G. (2007). White matter and cognitive
function in schizophrenia. Int. J. Neuropsychopharmacol. 10, 513–536. doi:
10.1017/S1461145707007638
English, J. A., Dicker, P., Föcking, M., Dunn, M. J., and Cotter, D. R. (2009). 2-
D DIGE analysis implicates cytoskeletal abnormalities in psychiatric disease.
Proteomics 9, 3368–3382. doi: 10.1002/pmic.200900015
Föcking, M., Dicker, P., English, J. A., Schubert, K. O., Dunn, M. J., and
Cotter, D. R. (2011). Common proteomic changes in the hippocampus in
schizophrenia and bipolar disorder and particular evidence for involvement
of cornu ammonis regions 2 and 3. Arch. Gen. Psychiatry 68, 477–488. doi:
10.1001/archgenpsychiatry.2011.43
Föcking, M., Lopez, L. M., English, J. A., Dicker, P., Wolff, A., Brindley, E., et al.
(2015). Proteomic and genomic evidence implicates the postsynaptic density in
schizophrenia.Mol. Psychiatry 20, 424–432. doi: 10.1038/mp.2014.63
Frith, C., and Dolan, R. (1996). The role of the prefrontal cortex in higher
cognitive functions. Brain Res. Cogn. Brain Res. 5, 175–181. doi: 10.1016/S0926-
6410(96)00054-7
Geromanos, S. J., Vissers, J. P., Silva, J. C., Dorschel, C. A., Li, G. Z.,
Gorenstein, M. V., et al. (2009). The detection, correlation, and comparison
of peptide precursor and product ions from data independent LC-MS with data
dependant LC-MS/MS. Proteomics 9, 1683–1695. doi: 10.1002/pmic.200800562
Glantz, L. A., and Lewis, D. A. (2000). Decreased dendritic spine density on
prefrontal cortical pyramidal neurons in schizophrenia. Arch. Gen. Psychiatry
57, 65–73. doi: 10.1001/archpsyc.57.1.65
Goldman, D., Merril, C. R., and Ebert, M. H. (1980). Two-dimensional gel
electrophoresis of cerebrospinal fluid proteins. Clin. Chem. 26, 1317–1322.
Guest, P. C., Chan, M. K., Gottschalk, M. G., and Bahn, S. (2014). The
use of proteomic biomarkers for improved diagnosis and stratification of
schizophrenia patients. Biomark. Med. 8, 15–27. doi: 10.2217/bmm.13.83
Guest, P. C., Martins-de-Souza, D., Schwarz, E., Rahmoune, H., Alsaif, M.,
Tomasik, J., et al. (2013). Proteomic profiling in schizophrenia: enabling
stratification for more effective treatment. Genome Med. 5, 25. doi:
10.1186/gm429
Guest, P. C., Schwarz, E., Krishnamurthy, D., Harris, L. W., Leweke, F. M.,
Rothermundt, M., et al. (2011). Altered levels of circulating insulin and
other neuroendocrine hormones associated with the onset of schizophrenia.
Psychoneuroendocrinology 36, 1092–1096. doi: 10.1016/j.psyneuen.2010.12.018
Guest, P. C., Wang, L., Harris, L. W., Burling, K., Levin, Y., Ernst, A., et al.
(2010). Increased levels of circulating insulin-related peptides in first-onset,
antipsychotic naive schizophrenia patients. Mol. Psychiatry 15, 118–119. doi:
10.1038/mp.2009.81
Haas, W., Faherty, B. K., Gerber, S. A., Elias, J. E., Beausoleil, S. A., Bakalarski,
C. E., et al. (2006). Optimization and use of peptide mass measurement
accuracy in shotgun proteomics. Mol. Cell. Proteomics 5, 1326–1337. doi:
10.1074/mcp.M500339-MCP200
Hanash, S. M., Pitteri, S. J., and Faca, V. M. (2008). Mining the plasma proteome
for cancer biomarkers. Nature 452, 571–579. doi: 10.1038/nature06916
Haroutunian, V., Katsel, P., Roussos, P., Davis, K. L., Altshuler, L. L., and Bartzokis,
G. (2014). Myelination, oligodendrocytes, and serious mental illness. Glia 62,
1856–1877. doi: 10.1002/glia.22716
Harrison, P. J., and Eastwood, S. L. (2001). Neuropathological studies of synaptic
connectivity in the hippocampal formation in schizophrenia. Hippocampus 11,
508–519. doi: 10.1002/hipo.1067
Hashimoto, T., Volk, D. W., Eggan, S. M., Mirnics, K., Pierri, J. N., Sun,
Z., et al. (2003). Gene expression deficits in a subclass of GABA neurons
in the prefrontal cortex of subjects with schizophrenia. J. Neurosci. 23,
6315–6326.
Herbert, J., Wilcox, J. N., Pham, K. T., Fremeau, R. T. Jr., Zeviani, M., Dwork,
A., et al. (1986). Transthyretin: a choroid plexus-specific transport protein in
human brain. The 1986 S. Weir Mitchell award. Neurology 36, 900–911. doi:
10.1212/WNL.36.7.900
Herberth, M., Koethe, D., Cheng, T. M., Krzyszton, N. D., Schoeffmann, S.,
Guest, P. C., et al. (2011). Impaired glycolytic response in peripheral blood
mononuclear cells of first-onset antipsychotic-naive schizophrenia patients.
Mol. Psychiatry 16, 848–859. doi: 10.1038/mp.2010.71
Huang, J. T., Leweke, F. M., Oxley, D., Wang, L., Harris, N., Koethe, D., et al.
(2006). Disease biomarkers in cerebrospinal fluid of patients with first-onset
psychosis. PLoS Med. 3:e428. doi: 10.1371/journal.pmed.0030428
Huang, T. J., Wang, L., Prabakaran, S., Wengenroth, M., Lockstone, H. E., Bahn,
S. et al. (2008). Independent protein-profiling studies show a decrease in
apolipoprotein A1 levels in schizophrenia CSF, brain and peripheral tissues.
Mol. Psychiatry 13, 1118–1128. doi: 10.1038/sj.mp.4002108
Iavarone, F., Melis, M., Platania, G., Cabras, T., Manconi, B., Petruzzelli, R.,
et al. (2014). Characterization of salivary proteins of schizophrenic and bipolar
disorder patients by top-down proteomics. J. Proteomics 103, 15–22. doi:
10.1016/j.jprot.2014.03.020
Innocenti, G. M., Ansermet, F., and Parnas, J. (2003). Schizophrenia,
neurodevelopment and corpus callosum. Mol. Psychiatry 8, 261–274. doi:
10.1038/sj.mp.4001205
Jaros, J. A., Martins-de-Souza, D., Rahmoune, H., Rothermundt, M., Leweke, F.
M., Guest, P. C., et al. (2012). Protein phosphorylation patterns in serum
from schizophrenia patients and healthy controls. J. Proteomics 76, 43–55. doi:
10.1016/j.jprot.2012.05.027
Jiang, L., Lindpaintner, K., Li, H. F., Gu, N. F., Langen, H., He, L., et al. (2003).
Proteomic analysis of the cerebrospinal fluid of patients with schizophrenia.
Amino Acids 25, 49–57. doi: 10.1007/s00726-003-0356-6
Johnston-Wilson, N. L., Sims, C. D., Hofmann, J. P., Anderson, L., Shore, A. D.,
Torrey, E. F., et al. (2000). Disease-specific alterations in frontal cortex brain
proteins in schizophrenia, bipolar disorder, andmajor depressive disorder.Mol.
Psychiatry 5, 142–149. doi: 10.1038/sj.mp.4000696
Kelleher, N. L. (2004). Top-down proteomics. Anal, Chem. 76, 197A–203A. doi:
10.1021/ac0415657
Kim, M. S., Pinto, S. M., Getnet, D., Nirujogi, R. S., Manda, S. S., Pandey, A.,
et al. (2014). A draft map of the human proteome. Nature 509, 575–581. doi:
10.1038/nature13302
Korolainen, M. A., Nyman, T. A., Aittokallio, T., and Pirttilä, T. (2010). An update
on clinical proteomics in Alzheimer’s research. J. Neurochem. 112, 1386–1414.
doi: 10.1111/j.1471-4159.2009.06558.x
Krishnamurthy, D., Harris, L. W., Levin, Y., Koutroukides, T. A., Rahmoune,
H., Pietsch, S., et al. (2013). Metabolic, hormonal and stress-related molecular
changes in post-mortem pituitary glands from schizophrenia subjects.World J.
Biol. Psychiatry 14, 478–489. doi: 10.3109/15622975.2011.601759
Frontiers in Cellular Neuroscience | www.frontiersin.org 20 February 2016 | Volume 10 | Article 18
Davalieva et al. Proteomics Research in Schizophrenia
Kroksveen, A. C., Opsahl, J. A., Aye, T. T., Ulvik, R. J., and Berven, F. S.
(2011). Proteomics of human cerebrospinal fluid: discovery and verification
of biomarker candidates in neurodegenerative diseases using quantitative
proteomics. J. Proteomics 74, 371–388. doi: 10.1016/j.jprot.2010.11.010
Kumanishi, T., Watabe, K., and Washiyama, K. (1985). An immunohistochemical
study of aldolase C in normal and neoplastic nervous tissues.Acta Neuropathol.
67, 309–314. doi: 10.1007/BF00687817
Levin, Y., Wang, L., Schwarz, E., Koethe, D., Leweke, F. M., and Bahn, S.
(2010). Global proteomic profiling reveals altered proteomic signature in
schizophrenia serum.Mol. Psychiatry 15, 1088–1100. doi: 10.1038/mp.2009.54
Li, G. Z., Vissers, J. P., Silva, J. C., Golick, D., Gorenstein, M. V., and Geromanos,
S. J. (2009). Database searching and accounting of multiplexed precursor and
product ion spectra from the data independent analysis of simple and complex
peptide mixtures. Proteomics 9, 1696–1719. doi: 10.1002/pmic.200800564
Li, Y., Zhou, K., Zhang, Z., Sun, L., Yang, J., Zhang, M., et al. (2012).
Label-free quantitative proteomic analysis reveals dysfunction of complement
pathway in peripheral blood of schizophrenia patients: evidence for the
immune hypothesis of schizophrenia. Mol. Biosyst. 8, 2664–2671. doi:
10.1039/c2mb25158b
Link, A. J., Eng, J., Schieltz, D. M., Carmack, E., Mize, G. J., Morris, D. R. III.
et al. (1999). Direct analysis of protein complexes usingmass spectrometry.Nat.
Biotechnol. 17, 676–682. doi: 10.1038/10890
Luu, P., and Posner, M. I. (2003). Anterior cingulate cortex regulation of
sympathetic activity. Brain 126, 2119–2120. doi: 10.1093/brain/awg257
Martins-de-Souza, D. (2010). Proteome and transcriptome analysis suggests
oligodendrocyte dysfunction in schizophrenia. J. Psychiatr. Res. 44, 149–156.
doi: 10.1016/j.jpsychires.2009.07.007
Martins-de-Souza, D. (2014). Proteomics, metabolomics, and protein
interactomics in the characterization of the molecular features of major
depressive disorder. Dialogues Clin. Neurosci. 16, 63–73.
Martins-de-Souza, D., Gattaz, W. F., Schmitt, A., MacCarrone, G., Hunyadi-
Gulyas, E., Eberlin, M. N., et al. (2009a). Proteomic analysis of dorsolateral
prefrontal cortex indicates the involvement of cytoskeleton, oligodendrocyte,
energy metabolism and new potential markers in schizophrenia. J. Psychiatr.
Res. 43, 978–986. doi: 10.1016/j.jpsychires.2008.11.006
Martins-de-Souza, D., Gattaz, W. F., Schmitt, A., Novello, J. C., Marangoni, S.,
Turck, C. W., et al. (2009b). Proteome analysis of schizophrenia patients
Wernicke’s area reveals an energy metabolism dysregulation. BMC Psychiatry
9:17. doi: 10.1186/1471-244X-9-17
Martins-de-Souza, D., Gattaz, W. F., Schmitt, A., Rewerts, C., MacCarrone,
G., Dias-Neto, E., et al. (2009c). Prefrontal cortex shotgun proteome
analysis reveals altered calcium homeostasis and immune system imbalance
in schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 259, 151–163. doi:
10.1007/s00406-008-0847-2
Martins-de-Souza, D., Gattaz, W. F., Schmitt, A., Rewerts, C., Marangoni, S.,
Novello, J. C., et al. (2009d). Alterations in oligodendrocyte proteins, calcium
homeostasis and new potential markers in schizophrenia anterior temporal
lobe are revealed by shotgun proteome analysis. J. Neural Transm. 116,
275–289. doi: 10.1007/s00702-008-0156-y
Martins-de-Souza, D., Guest, P. C., Harris, L. W., Vanattou-Saifoudine, N.,
Webster, M. J., Rahmoune, H., et al. (2012a). Identification of proteomic
signatures associated with depression and psychotic depression in post-
mortem brains from major depression patients. Transl. Psychiatry 2, e87. doi:
10.1038/tp.2012.13
Martins-de-Souza, D., Guest, P. C., Rahmoune, H., and Bahn, S. (2012b).
Proteomic approaches to unravel the complexity of schizophrenia. Expert Rev.
Proteomics 9, 97–108. doi: 10.1586/epr.11.70
Martins-de-Souza, D., Maccarrone, G., Wobrock, T., Zerr, I., Gormanns,
P., Reckow, S., et al. (2010a). Proteome analysis of the thalamus and
cerebrospinal fluid reveals glycolysis dysfunction and potential biomarkers
candidates for schizophrenia. J. Psychiatr. Res. 44, 1176–1189. doi:
10.1016/j.jpsychires.2010.04.014
Martins-de-Souza, D., Schmitt, A., Roder, R., Lebar, M., Schneider-Axmann,
T., Falkai, P., et al. (2010b). Sex-specific proteome differences in the
anterior cingulate cortex of schizophrenia. J. Psychiatr. Res. 44, 989–991. doi:
10.1016/j.jpsychires.2010.03.003
Martins-De-Souza, D.,Wobrock, T., Zerr, I., Schmitt, A., Gawinecka, J., Schneider-
Axmann, T., et al. (2010c). Different apolipoprotein E, apolipoprotein A1 and
prostaglandin-H2 D-isomerase levels in cerebrospinal fluid of schizophrenia
patients and healthy controls. World J. Biol. Psychiatry 11, 719–728. doi:
10.3109/15622971003758748
McCullumsmith, R. E., Gupta, D., Beneyto, M., Kreger, E., Haroutunian, V., Davis,
K. L., et al. (2007). Expression of transcripts for myelination-related genes in
the anterior cingulate cortex in schizophrenia. Schizophr. Res. 90, 15–27. doi:
10.1016/j.schres.2006.11.017
Mehler, C., and Warnke, A. (2002). Structural brain abnormalities specific
to childhood-onset schizophrenia identified by neuroimaging techniques. J.
Neural Transm. 109, 219–234. doi: 10.1007/s007020200019
Mei, J. F., Kolbin, D., Kao, H. T., and Porton, B. (2006). Protein expression
profiling of postmortem brain in schizophrenia. Schizophr. Res. 84, 204–213.
doi: 10.1016/j.schres.2006.02.016
Michalski, A., Damoc, E., Lange, O., Denisov, E., Nolting, D., Müller,
M., et al. (2012). Ultra high resolution linear ion trap Orbitrap mass
spectrometer (Orbitrap Elite) facilitates top down LC MS/MS and versatile
peptide fragmentation modes. Mol. Cell. Proteomics 11, O111.013698. doi:
10.1074/mcp.O111.013698
Miller, E. K., and Cohen, J. D. (2001). An integrative theory of
prefrontal cortex function. Annu. Rev. Neurosci. 24, 167–202. doi:
10.1146/annurev.neuro.24.1.167
Montague, E., Janko, I., Stanberry, L., Lee, E., Choiniere, J., Anderson, N., et al.
(2015). Beyond protein expression, MOPED goes multi-omics. Nucleic Acids
Res. 43, D1145–D1151. doi: 10.1093/nar/gku1175
Nascimento, J. M., and Martins-de-Souza, D. (2015). The proteome of
schizophrenia. Npj Schizophrenia 1, 14003. doi: 10.1038/npjschz.2014.3
Nesvaderani, M., Matsumoto, I., and Sivagnanasundaram, S. (2009).
Anterior hippocampus in schizophrenia pathogenesis: molecular evidence
from a proteome study. Aus. N.Z. J. Psychiatry 43, 310–322. doi:
10.1080/00048670902721103
Novikova, S. I., He, F., Cutrufello, N. J., and Lidow, M. S. (2006). Identification
of protein biomarkers for schizophrenia and bipolar disorder in the
postmortem prefrontal cortex using SELDI-TOF-MS ProteinChip profiling
combined with MALDI-TOF-PSD-MS analysis. Neurobiol. Dis. 23, 61–76. doi:
10.1016/j.nbd.2006.02.002
O’Farrell, P. H. (1975). High resolution two-dimensional electrophoresis of
proteins. J. Biol. Chem. 250, 4007–4021.
Owen, M. J., Craddock, N., and O’Donovan, M. C. (2010). Suggestion of roles for
both common and rare risk variants in genome-wide studies of schizophrenia.
Arch. Gen. Psychiatry 67, 667–673. doi: 10.1001/archgenpsychiatry.2010.69
Park, S., and Holzman, P. S. (1992). Schizophrenics show spatial
working memory deficits. Arch. Gen. Psychiatry 49, 975–982. doi:
10.1001/archpsyc.1992.01820120063009
Park, S., and Holzman, P. S. (1993). Association of working memory deficit
and eye tracking dysfunction in schizophrenia. Schizophr. Res. 11, 55–61. doi:
10.1016/0920-9964(93)90038-K
Patel, V. J., Thalassinos, K., Slade, S. E., Connolly, J. B., Crombie, A., Murrell, J. C.,
et al. (2009). A comparison of labeling and label-free mass spectrometry-based
proteomics approaches. J. Proteome Res. 8, 3752–3759. doi: 10.1021/pr900080y
Pennington, K., Beasley, C. L., Dicker, P., Fagan, A., English, J., Pariante, C. M.,
et al. (2008). Prominent synaptic and metabolic abnormalities revealed by
proteomic analysis of the dorsolateral prefrontal cortex in schizophrenia and
bipolar disorder.Mol. Psychiatry 13, 1102–1117. doi: 10.1038/sj.mp.4002098
Petrak, J., Ivanek, R., Toman, O., Cmejla, R., Cmejlova, J., Vyoral, D., et al. (2008).
Deja vu in proteomics. A hit parade of repeatedly identified differentially
expressed proteins. Proteomics 8, 1744–1749. doi: 10.1002/pmic.200700919
Prabakaran, S., Swatton, J. E., Ryan, M. M., Huffaker, S. J., Huang, T. J.,
Bahn, S., et al. (2004). Mitochondrial dysfunction in schizophrenia: evidence
for compromised brain metabolism and oxidative stress. Mol. Psychiatry 9,
684–697. doi: 10.1038/sj.mp.4001532
Quintana, J., Wong, T., Ortiz-Portillo, E., Marder, S. R., andMazziotta, J. C. (2004).
Anterior cingulate dysfunction during choice anticipation in schizophrenia.
Psychiatry Res. 132, 117–130. doi: 10.1016/j.pscychresns.2004.06.005
Rabilloud, T., and Lelong, C. (2011). Two-dimensional gel electrophoresis
in proteomics: a tutorial. J. Proteomics 74, 1829–1841. doi:
10.1016/j.jprot.2011.05.040
Raiszadeh, M. M., Ross, M. M., Russo, P. S., Schaepper, M. A., Zhou, W., Deng, J.,
et al. (2012). Proteomic analysis of eccrine sweat: implications for the discovery
Frontiers in Cellular Neuroscience | www.frontiersin.org 21 February 2016 | Volume 10 | Article 18
Davalieva et al. Proteomics Research in Schizophrenia
of schizophrenia biomarker proteins. J. Proteome Res. 11, 2127–2139. doi:
10.1021/pr2007957
Romanski, L. M., Giguere, M., Bates, J. F., and Goldman-Rakic, P. S. (1997).
Topographic organization of medial pulvinar connections with the prefrontal
cortex in the rhesus monkey. J. Comp. Neurol. 379, 313–332.
Saia-Cereda, V. M., Cassoli, J. S., Schmitt, A., Falkai, P., Nascimento, J. M.,
and Martins-de-Souza, D. (2015). Proteomics of the corpus callosum unravel
pivotal players in the dysfunction of cell signaling, structure, and myelination
in schizophrenia brains. Eur. Arch. Psychiatry Clin. Neurosci. 265, 601–612. doi:
10.1007/s00406-015-0621-1
Salgado-Pineda, P., Baeza, I., Pérez-Gómez, M., Vendrell, P., Junqué, C., Bargalló,
N., et al. (2003). Sustained attention impairment correlates to gray matter
decreases in first episode neuroleptic-naive schizophrenic patients.Neuroimage
19, 365–375. doi: 10.1016/S1053-8119(03)00094-6
Schwarz, E., Guest, P. C., Rahmoune, H., Harris, L. W., Wang, L., Leweke, F.
M., et al. (2012a). Identification of a biological signature for schizophrenia in
serum.Mol. Psychiatry 17, 494–502. doi: 10.1038/mp.2011.42
Schwarz, E., Guest, P. C., Rahmoune, H., Martins-de-Souza, D., Niebuhr, D.
W., Weber, N. S., et al. (2012b). Identification of a blood-based biological
signature in subjects with psychiatric disorders prior to clinical manifestation.
World J. Biol. Psychiatry 13, 627–632. doi: 10.3109/15622975.2011.
599861
Schwarz, E., Guest, P. C., Steiner, J., Bogerts, B., and Bahn, S. (2012c). Identification
of blood-based molecular signatures for prediction of response and relapse in
schizophrenia patients. Transl. Psychiatry 2, e82. doi: 10.1038/tp.2012.3
Schwarz, E., Izmailov, R., Spain, M., Barnes, A., Mapes, J. P., Guest, P. C., et al.
(2010). Validation of a blood-based laboratory test to aid in the confirmation of
a diagnosis of schizophrenia. Biomark. Insights 5, 39–47.
Schwarz, E., van Beveren, N. J., Ramsey, J., Leweke, F. M., Rothermundt, M.,
Bogerts, B., et al. (2014). Identification of subgroups of schizophrenia patients
with changes in either immune or growth factor and hormonal pathways.
Schizophr. Bull. 40, 787–795. doi: 10.1093/schbul/sbt105
Seeley, E. H., and Caprioli, R. M. (2008). Molecular imaging of proteins in tissues
by mass spectrometry. Proc. Natl. Acad. Sci. U.S.A. 105, 18126–18131. doi:
10.1073/pnas.0801374105
Selemon, L. D., Rajkowska, G., and Goldman-Rakic, P. S. (1995). Abnormally
high neuronal density in the schizophrenic cortex. A morphometric analysis
of prefrontal area 9 and occipital area 17. Arch. Gen. Psychiatry 52, 805–818.
doi: 10.1001/archpsyc.1995.03950220015005
Shenton, M. E., Dickey, C. C., Frumin, M., and McCarley, R. W. (2001). A review
of MRI findings in schizophrenia. Schizophr. Res. 49, 1–52. doi: 10.1016/S0920-
9964(01)00163-3
Sivagnanasundaram, S., Crossett, B., Dedova, I., Cordwell, S., and Matsumoto,
I. (2007). Abnormal pathways in the genu of the corpus callosum in
schizophrenia pathogenesis: a proteome study. Proteomics Clin. Appl. 1,
1291–1305. doi: 10.1002/prca.200700230
Smalla, K. H., Mikhaylova, M., Sahin, J., Bernstein, H. G., Bogerts, B., Schmitt,
A., et al. (2008). A comparison of the synaptic proteome in human chronic
schizophrenia and rat ketamine psychosis suggest that prohibitin is involved
in the synaptic pathology of schizophrenia. Mol. Psychiatry 13, 878–896. doi:
10.1038/mp.2008.60
Srivastava, G., Singh, K., Tiwari, M. N., and Singh, M. P. (2010). Proteomics in
Parkinson’s disease: current trends, translational snags and future possibilities.
Expert Rev. Proteomics 7, 127–139. doi: 10.1586/epr.09.91
Stahl, D. C., Swiderek, K. M., Davis, M. T., and Lee, T. D. (1996). Data-controlled
automation of liquid chromatography/tandem mass spectrometry analysis of
peptide mixtures. J. Am. Soc. Mass Spectrom. 7, 532–540. doi: 10.1016/1044-
0305(96)00057-8
Steiner, J., Schmitt, A., Schroeter, M. L., Bogerts, B., Falkai, P., Turck, C. W.,
et al. (2014). S100B is downregulated in the nuclear proteome of schizophrenia
corpus callosum. Eur. Arch. Psychiatry Clin. Neurosci. 264, 311–316. doi:
10.1007/s00406-014-0490-z
Sullivan, P. F., Daly, M. J., and O’Donovan, M. (2012). Genetic architectures
of psychiatric disorders: the emerging picture and its implications. Nat. Rev.
Genet. 13, 537–551. doi: 10.1038/nrg3240
Tanaka, J., and Sobue, K. (1994). Localization and characterization of gelsolin
in nervous tissues: gelsolin is specifically enriched in myelin-forming cells. J.
Neurosci. 14, 1038–1052.
Thompson, R. J., Kynoch, P. A., and Willson, V. J. (1982). Cellular localization
of aldolase C subunits in human brain. Brain Res. 232, 489–493. doi:
10.1016/0006-8993(82)90294-3
Unlü, M., Morgan, M. E., and Minden, J. S. (1997). Difference gel electrophoresis:
a single gel method for detecting changes in protein extracts. Electrophoresis 18,
2071–2077. doi: 10.1002/elps.1150181133
Varadarajulu, J., Schmitt, A., Falkai, P., Alsaif, M., Turck, C. W., and Martins-
de-Souza, D. (2012). Differential expression of HINT1 in schizophrenia brain
tissue. Eur. Arch. Psychiatry Clin. Neurosci. 262, 167–172. doi: 10.1007/s00406-
011-0216-4
Velligan, D. I., and Bow-Thomas, C. C. (1999). Executive function in
schizophrenia. Semin. Clin. Neuropsychiatry 4, 24–33.
Wan, C., La, Y., Zhu, H., Yang, Y., Jiang, L., Chen, Y., et al. (2007). Abnormal
changes of plasma acute phase proteins in schizophrenia and the relation
between schizophrenia and haptoglobin (Hp) gene. Amino Acids 32, 101–108.
doi: 10.1007/s00726-005-0292-8
Wang, P., Bouwman, F. G., andMariman, E. C. (2009). Generally detected proteins
in comparative proteomics–a matter of cellular stress response? Proteomics 9,
2955–2966. doi: 10.1002/pmic.200800826
Wright, E. P., Partridge, M. A., Padula, M. P., Gauci, V. J., Malladi, C.
S., and Coorssen, J. R. (2014a). Top-down proteomics: enhancing 2D gel
electrophoresis from tissue processing to high-sensitivity protein detection.
Proteomics 14, 872–889. doi: 10.1002/pmic.201300424
Wright, E. P., Prasad, K. A., Padula, M. P., and Coorssen, J. R. (2014b).
Deep imaging: how much of the proteome does current top-down
technology already resolve? PLoS ONE 9:e86058. doi: 10.1371/journal.pone.00
86058
Wright, G. L. Jr. (2002). SELDI proteinchip MS: a platform for biomarker
discovery and cancer diagnosis. Expert Rev. Mol. Diagn. 2, 549–563. doi:
10.1586/14737159.2.6.549
Yamasaki, R., Lu, H., Butovsky, O., Ohno, N., Rietsch, A. M., Cialic, R.,
et al. (2014). Differential roles of microglia and monocytes in the inflamed
central nervous system. J. Exp. Med. 211, 1533–1549. doi: 10.1084/jem.201
32477
Yang, Y., Wan, C., Li, H., Zhu, H., La, Y., Xi, Z., et al. (2006). Altered levels of acute
phase proteins in the plasma of patients with schizophrenia. Anal. Chem. 78,
3571–3576. doi: 10.1021/ac051916x
Ye, H., Mandal, R., Catherman, A., Thomas, P. M., Kelleher, N. L., Ikonomidou,
C., et al. (2014). Top-down proteomics with mass spectrometry imaging: a pilot
study towards discovery of biomarkers for neurodevelopmental disorders. PLoS
ONE 9:e92831. doi: 10.1371/journal.pone.0092831
Zhang, Y., Chen, K., Sloan, S. A., Bennett, M. L., Scholze, A. R., O’Keeffe, S.,
et al. (2014). An RNA-sequencing transcriptome and splicing database of glia,
neurons, and vascular cells of the cerebral cortex. J. Neurosci. 34, 11929–11947.
doi: 10.1523/JNEUROSCI.1860-14.2014
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2016 Davalieva, Maleva Kostovska and Dwork. This is an open-access
article distributed under the terms of the Creative Commons Attribution License (CC
BY). The use, distribution or reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution
or reproduction is permitted which does not comply with these terms.
Frontiers in Cellular Neuroscience | www.frontiersin.org 22 February 2016 | Volume 10 | Article 18
